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PROGNOSTIC FACTORS FOR BLADDER AND PROSTATE CANCER 
Chapter I 
Introduction and outline of thesis. 
Based on: 
Rainy Umbas, Frans M. J. Debruyne and Jack A. Schalken: Genetic basis of prostate cancer 
development. In: Sex hormones and antihormones in endocrine dependent pathology: basic 
and clinical aspects.,(M. Motta and M. Serio, editors), 1-7, 1994 
4 Introduction 
Introduction. 
Currently, cancer of the prostate and bladder are the most encountered malignancies in 
urological practice. The natural course and treatment outcome of these cancers are largely 
unpredictable. Thus, knowledge of prognostic indicators for the biological potential of these 
cancers is likely to become important not only in the management of patients in daily 
practice but also as one of the considerations for selection criteria in clinical trials aimed at 
developing new treatment modalities. The prognostic factors available to date can be 
grouped into several categories and will be discussed in this chapter. 
1. Prognostic factors in prostate cancer. 
Prostate cancer is one of the most prevalent forms of malignancies, and has become the 
second cause of cancer related death in men (Boring, 1993). At the time of diagnosis the 
disease is in advanced stage (>pT2) in more than 40% of the patients and most of them will 
succumb to their disease (Kozlowszki 1991, Goodman 1991). In the last years improvements 
in the diagnosis of prostate cancer (i.e., digital rectal examination, transrectal 
ultrasonography, and serum PSA level) have now resulted in early detection programs that 
reveal many more organ confined lesions that can be treated radically (Cooner 1990, 
Oesterling 1991, Scardino 1992, Eble 1992). Whether this truly improves overall survival is 
not clear, because of the unpredictable biological potential of these tumors. The clinical 
course of men with prostate cancer may vary widely, even in men whose tumors are of 
similar clinical stage and histological grade (George 1988, Grayhack 1983). Studies of the 
natural history of prostate cancer revealed that not every prostate cancer will progress 
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(Johansson 1989, Adolfson 1990a) and, on the other hand, metastases still develop in a 
considerable group of patients after radical treatment for localized disease as demonstrated 
in other studies (Myers 1983, Blute 1989). Hormonal therapy is one of the treatment 
modalities for patients with disseminated prostate cancer that has been used for more than 
50 years since the original observation by Huggins and colleagues (1941) and was extensively 
evaluated in the last years (Labrie 1989, 1990). Despite the development in androgen 
deprivation therapy as treatment of choice for advanced prostatic carcinoma, many studies 
demonstrated that the treatment outcome varies remarkably in this group of patients 
(Kozlowski 1991, Crawford 1991, Denis 1991). Thus, in daily practice it is useful to analyze 
the parameters that can serve as prognostic factor to predict the treatment response. The 
inclusion of these factors in the individual therapeutic decisions may contribute to an 
improvement of the treatment results that would in turn lead to an improvement of the 
survival rate. Prognostic factors will also be important in conducting new studies in order to 
determine which treatment modality should be given to individual patients based on (tumor) 
prognostic factor analysis. 
1.1. Clinical parameters. 
Age is still controversial to be used as prognostic factor (Berry 1979, Harrison 1983, Wilson 
1984, Emrich 1985, Soloway 1990, Ernst 1991). Bad performance status, usually categorized 
according to the Karnofsky classification, is mostly associated with shorter survival (Emrich 
1985, de Voogt 1989, Soloway 1990). Furthermore, this parameter is related with the 
advanced stage of the disease. Another clinical parameter is the tumor volume as proposed 
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by Bostwick and colleagues in the management of early prostate cancer (Bostwick & Choi, 
1992). Clinical evaluation of tumor volume and extent (i.e., digital rectal examination and 
imaging) were the standard methods to determine the clinical stage. Studies of the tumor 
volume demonstrated a significant correlation between increase of tumor volume and 
penetration through the capsule and seminal vesicle invasion. Evenmore, combination of 
tumor volume and percentage of high-grade tumor strongly correlated with lymph node 
metastasis (McNeal 1992). McNeal also demonstrated a strong correlation between tumor 
volume and loss of differentiation and rarely found evidence of invasiveness or metastasis 
in cancers smaller than 1 cm3 (McNeal 1986). Unfortunately, adequate volume determination 
of localized cancer is difficult without taking the whole prostate gland as in radical 
prostatectomy. Other studies showed that seminal vesicle invasion is correlated with poor 
prognosis in patients with prostate cancer; however, its close association with tumor volume 
and capsular penetration suggest that it has less independent prognostic value (Stamey 1988, 
Villers 1990). Extent of the bone metastatic disease which can be identified by imaging 
techniques, can be used to predict the patient survival (Soloway 1988, 1990, Ernst 1991). 
Soloway also demonstrated that extent of disease on bone scan, pretrealment testosterone 
level and performance status were significantly associated with progression-free survival in 
patients with metastatic prostate cancer (Soloway 1990). 
1.2. Histopathological parameters. 
In a multivariate analysis, Stege et al (1992) demonstrated that aspiration cytology of 
prostate cancercells is one of the most important predicting factors for interval to 
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progression in advanced stage patients beside tissue prostate specific antigen (PSA), 
particularly in high-grade tumors. Another parameter is tumor deoxyribonucleic acid (DNA) 
ploidy determined by flow cytometry or image analysis. Several studies demonstrated the 
value of DNA ploidy analysis in prostate cancer prognosis. The presence of non-diploid foci 
correlated with progression and survival, and stage (Tribukait 1983, Blute 1989, Greene 
1991, Wirth 1991, Forsslund 1992). In a retrospective study of radical prostatectomized 
patients, Nativ et al (Nativ 1990) found a good correlation between DNA ploidy and 
progression. They also found a strong association between DNA ploidy and preoperative 
serum PSA levels. As mentioned earlier, a study by Stege and colleagues also suggests a 
correlation between DNA ploidy and cytology since there is no significant contribution of 
ploidy when cytology is already considered in the multivariate analysis, and if the cytology 
is not included in the analysis the ploidy will replace it (Stege 1992). The ploidy of the lymph 
node metastases also correlated significantly with the rate of progression and time interval 
to progression (Stephenson 1987, Peters-Gee 1992). However, other studies (Blute 1989, 
Greene 1991) demonstrated that diploid tumors penetrate the capsule as frequently as non-
diploid ones, and diploid tumors also are progressive although more slowly (Adolfsson 
1990b). Tumor grade as one of the pathological parameters, is most often used to predict 
the biological potential. Two grading classifications, the Gleason and the Mostofi system are 
well-established and both have demonstrated their correlation with prognosis in prostatic 
carcinoma (Gleason 1974, Mostofi 1975). These systems provide adequate predictive value 
for tumors at either end of the differentiation spectrum (i.e., well and poorly differentiated) 
but one inadequate in determining the prognosis in the group of patients with 
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moderately/poorly differentiated tumors, that comprises the majority of cases (Partin 1989, 
Carter 1989). The pathological stage seems to be one of the best prognostic factors available 
to date, however, this parameter could be obtained only in those who had been treated by 
radical prostatectomy (Morton 1991). 
1.3. Biochemical parameters. 
Parameters that can be obtained from the clinical laboratory are attractive, because of 
logistic and financial reasons, and have been studied extensively during the last decades. The 
importance of hemoglobin (Hb) as prognostic factor for hormonally unresponsive prostate 
cancer patients treated with chemotherapy has been reported by Berry et al (1983). 
Hemoglobin, together with performance status and serum alkaline phosphatase also have 
been used to define three risk groups of prostate cancer patients that react differently on 
hormonal therapy (Mulders 1990). Low pretreatment serum testosterone level, less than 300 
ng/ml, correlated significantly with a shorter progression free interval in patients treated by 
androgen deprivation (Soloway 1990, Ernst 1991). Another biochemical parameter that has 
been used for years is prostate acid phosphatase (PAP) despite the likelihood of false-
positive results in some conditions (Stamey, in Campbell's 1992). Also, the value of PAP to 
predict progression towards skeletal metastases was less than the histological grade 
(Goodman 1991). In the last years, prostate specific antigen (PSA), another prostatic 
enzyme, has been studied widely and appears to be one of the most useful serum markers 
for prostate cancer (Oesterling 1991). Serum PSA measurements are superior to those of 
serum PAP in predicting disease recurrence in stage С and D prostate cancer patients 
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treated by combination endocrine therapy (Dupont 1991). In hormonally treated patients, 
the decrease in PSA level to less than 10 ng/ml after 6 months of therapy related to 
prolonged time to progression (Cooper 1990, Mulders 1992). Also, an increasing PSA level 
could predict the progression to bone metastasic disease before it appears on bone scan 
(Chybowski 1991, Mulders 1992). Nevertheless, besides its importance for detection and 
monitoring of prostate cancer, the role of PSA as a pretreatment prognostic factor has not 
yet been established. 
1.4. Molecular prognostic factors. 
Immunohistochemistry involves the application of antibodies onto tissue sections so that 
antigens can be identified in situ. The expression of intermediate filament proteins (IFPs), 
particularly keratins and vimentin has been examined in the Dunning R-3327 rat prostatic 
cancer cell-lines which represent the entire spectrum of progression of prostate cancer 
(Isaacs 1986). Using a variety of antibodies specific for keratins and vimentin, it was shown 
that a loss in staining for basal cell keratin (#14) and an increase in the immunoreactivity 
for vimentin was consistently associated with a more advanced stage of tumor progression 
(Ramaekers 1989). 
PAP and PSA as organ specific enzymes have been identified immunohistochemically in 
prostatic acini and ducts. Recently, Sakai et al. (1991) demonstrated a variety of PAP 
staining patterns in neoplastic prostate glands, and therefore proposed a semiquantitative 
grading system by adding the immunostaining intensity grade in the primary and secondary 
patterns. Thus it was shown that patients with high intensity of PAP expression have a better 
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survival rate compared to patients with low intensity of PAP immunoreactivity. Despite the 
important role of PSA in diagnosis and monitoring of prostate cancer, its value as an 
immunohistochemical prognostic factor is not yet established. Epstein and Eggleston showed 
a significant correlation between PSA staining heterogeneity and progression in a small 
number of low stage prostate cancer patients (Epstein 1984). 
Recently Cohen and colleagues described the value of the presence of neuro-endocrine cells 
as a prognostic parameter. They found that patients without expression of the neuro-
endocrine cell characteristics in their tumor specimens will have a better survival (Cohen 
1990, 1991). 
Oncogenes, growth factors, tumor suppressor genes (TSGs) and genes related to invasion 
and metastasis have gained increasing interest during the last years, particularly because of 
their potential role as prognostic indicators. Oncogene antigen 519 (OA-519), a 
haptoglobulin related protein, is overexpressed in high grade tumors, and this increase also 
correlated with tumor volume, and advanced stage. Thus, the acquisition of OA-519 
expression may serve as prognostic factor in prostate cancer (Shurbaji 1992). However, the 
correlation between expression of other oncogenes e.g., ras and myc, with progression in 
prostate cancer is still controversial (Carter 1990, Bussemakers 1991a, Ichikawa 1991, 
Gumerlock 1991). From the TSGs, the p53 gene has received most attention in numerous 
malignancies and also in relation to prostate cancer development. Whereas mutational 
inactivation of the p53 gene seems to be an infrequent event (Dinjens 1994), increased 
immunohistochemically detectable p53 was found to be of potential value (Kallakury 1994, 
Aprikian 1994). Another method to find molecular markers for aggressiveness is to identify 
Prognoslic factors for bladder and prostate cancer Ц 
mRNAs specifically expressed in metastatic tumor cells. Fibronectin, a protein that is 
important in adhesive interactions, was found to be down modulated in metastatic prostate 
cancer cells. Fibronectin mRNA level in the metastasizing tumor sublines of the Dunning 
R-3327 rat prostatic cell-lines was 4- to 8-fold lower than in the anaplastic nonmetastasizing 
sublines (Schalken 1988). However, the fact that well differentiated tumors also have a low 
expression of fibronectin hampered further application of these findings to diagnosis of 
prostate cancer (Unpublished observation). High mobility group -I and -Y [HMG-I(Y)] 
proteins, members of a family of proteins which are non-histone, chromatin binding, were 
found to be overexpressed in metastatic Dunning R-3327 rat prostatic cancer lines (Busse-
makers 1991b). More recently in a study on human prostate cancers, Tamimi et al. (1993) 
demonstrated that HMG-I(Y) expression assessed by RNA in situ hybridization is related 
to tumor differentiation. Finally, the cell-adhesion molecules have recently gained 
considerable attention as candidates for markers related to tumor invasive potential. In a 
previous study using the Dunning R-3327 rat prostatic cancer model system, the expression 
of E-cadherin, a member of the Ca2*-dependent homotypic homophylic cell-adhesion 
molecules (Takeichi 1988), was found to be expressed in the well and poorly differentiated 
lines with low invasive potential, while all established lines with high invasive potential had 
no detectable levels of E-cadherin expression. In a spontaneously arisen metastatic subline 
of the Dunning R-3327 rat prostate cancer cell lines, E-cadherin expression was also 
decreased (Bussemakers 1992). Interestingly, the long arm of chromosome 16 on which the 
E-cadherin gene has been mapped (Mansouri 1988) is deleted in 32% to 56% of human 
prostate carcinomas (Carter 1990, Bergerheim 1991). Recently, a study on human prostate 
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tumors demonstrated a statistically significant correlation between decreased expression of 
E-cadherin and increased grade (Umbas 1992, this thesis). This study found that all of the 
well-differentiated tumors (Gleason score 4 and 5) were homogeneously positive whereas 
all of the poorly differentiated and undifferentiated tumors (Gleason 9 and 10) had either 
heterogeneous or negative staining. Moreover, decreased expression had prognostic value, 
i.e. there was a significant correlation with progression after radical surgery and decreased 
survival after palliative TURP (Umbas, 1994, this thesis). These results suggest that 
decreased expression of E-cadherin is associated with progression of prostate cancer and 
should be studied in the clinical setting. 
2. Prognostic factors in bladder cancer. 
Bladder cancer is the second most prevalent urological malignancy (Boring 1993) which is 
also characterized by a diverse biological behaviour. This causes a therapeutic dilemma, i.e. 
should a conservative or radical treatment be offered? Approximately 70-85% of bladder 
cancer patients have superficial [pTa, pTl, and/or carcinoma in situ (CIS)] tumors at the 
time of clinical presentation (American Cancer Society 1987). Superficial bladder cancer is 
characterized by a high recurrence rate, ranging from 50 to 80%, most frequently in the first 
year after transurethral resection (TUR) of the tumor (Lutzeyer 1982, Fitzpatrick 1986, Haaf 
1986). Even more threatening is the risk of tumor progression towards invasive cancer which 
is estimated to occur in 25-30% of the superficial tumors (Heney 1983, Herr 1991). It is 
obvious that inclusion of prognostic factors is important in individual therapeutic decisions 
for instance to change to a more aggressive therapeutic modality before tumor progression 
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occurs. At present, most of the parameters studied provide only general guidelines for the 
clinical management and none provides reliable information which specifically correlates with 
the prognosis of an individual tumor and the variability in behaviour between tumors with 
apparently similar features (Abel 1988, Heney 1992) is probably due to the low specificity 
of the prognostic tools available to date. Therefore, patients suffering from superficial 
transitional cell carcinoma undergo regular cystoscopical examinations to establish whether 
the bladder is macroscopically disease free and biopsy specimens are taken to be examined 
microscopically in case of suspicious lesion(s) in the bladder. Despite the likelihood of 
negative results (Meuleman 1988, Prout 1992), this is the only follow-up procedure that is 
generally accepted at this moment as the "gold standard" for follow-up of patients with 
superficial bladder cancer. 
2.1. Clinical parameters. 
Patients younger than 30 years will usually have low stage tumor which is associated with a 
relatively benign behaviour (Witjes 1989). However, in patients older then 30, age has no 
clear prognostic value (Narayana 1983, Herr 1989, Takashi 1989). Sex as prognostic indicator 
is controversial; a study by Hickey and Soloway (Hickey 1988) showed that at time of 
cystectomy tumor stage was higher in females than in males, 59% (T4) and 18% (T3) 
respectively, whereas other studies (Herr 1989, Takashi 1989) did not support these findings. 
Radiographic characteristics have been investigated as prognostic factor. Dilatation of the 
ureter on intravenous urography (IVU) may indicate muscle invasive disease, and herewith 
associated a worse prognosis (Hatch 1986, Golding 1987). Mameghan and Fisher (1989) 
14 Introduction 
found that ureteric obstruction has independent prognostic value in patients treated by 
radiotherapy with or without cystectomy. Nevertheles, Greven et al. (1990) found no 
significant difference of the survival between patients with hydronephrosis on initial IVU 
compared to patients without. Tumor multiplicity is associated with an increased risk of 
recurrence and/or progression of the disease (Lutzeyer 1982, Cutler 1982, Jakse 1987). 
Dalesio et al. (1983) reported that in most patients treated with TUR and TUR with 
chemotherapy, tumor multiplicity is the single most important factor affecting the recurrence 
rate using a Cox's linear regression model. A study by the British Medical Research Council 
group also found similar results in a multivariate analysis of patients with superficial bladder 
cancer (Parmar 1989). Herr and associates (1989) evaluated 228 patients treated with TUR 
and intravesical installation of Bacillus Calmette-Guérin (BCG) and found that tumor 
multiplicity was a highly significant factor in progression by using univariate analysis but not 
in a multivariate analysis including grade, cytological findings, and history of bladder cancer. 
Tumor size was also considered as a factor that affected prognosis. Tumors larger than 5 cm 
were associated with shorter disease free intervals (Heney 1983). Similarly, Jakse et al. 
(1987) found that tumors larger than 2 cm had an increased risk for recurrences. On the 
other hand, various other studies did not show a correlation between tumor size and 
prognosis (Kurth 1984, Rübben 1988, Takashi 1989). Hence, one cannot draw a conclusion 
from these studies since they used different thresholds for tumor size as parameter. Another 
parameter which correlates with the risk of tumor progression is recurrence rate as revealed 
in multivariate analysis of European Organization for Reseach and Treatment of Cancer 
(EORTC) Genito-Urinary (GU) group studies (Kurth 1990). 
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2.2. Biochemical parameters. 
At present, no tumor markers of high sensitivity and specificity for bladder cancer have been 
identified. Ackermann reviewed the role of carcinoembryonic antigen (CEA) and reported 
a wide range of CEA levels in blood of bladder cancer patients (Ackermann 1985). 
Increased levels of serum carbohydrate antigen 19.9 (CA 19.9) might be important in 
monitoring the natural history of bladder cancer, however, its value as a prognostic indicator 
is still questionable (Abel 1987). Another promising tumor marker is the tissue polypeptide 
antigen (TPA). Except for tumor diagnosis, plasma TPA concentration showed a good 
correlation with tumor progression as well as regression after treatment in urothelial bladder 
cancer (Adolphs 1984). Later on, Carbin et al. (1989) suggested the important role of 
urinary TPA (U-TPA) as an indicator of bladder cancer recurrence. One disadvantage of 
this method is the necessity to use 24 hours urine samples to avoid the effect of circadian 
rhythms (Kumar 1981, Costello 1985). 
2.3. Histopathological parameters. 
Heney et al. (1983) found a statistically significant difference of the duration of disease free 
interval between patients with negative and positive urinary cytology. Herr et al. (1989) also 
found a significant correlation between urinary cytology and progression of superficial 
cancers treated with BCG. The low reproducibility of cytopathology, however, makes this a 
less useful parameter. The accuracy might be increased by using transitional cell carcinoma 
monoclonal antibodies (Fradet 1986, 1987, 1990, Huland 1990). However, because of the 
striking association between tumor grade and positive cytology, it seems that this correlation 
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is a function of tumor grade (Heney 1983). Tumor DNA ploidy, determined by 
flowcytometry (FCM) or image analysis, as a parameter for tumor progression or recurrence 
has been increasingly studied in the last years. Murphy et al. (1986) found that almost all 
grade I transitional cell carcinomas (TCCs) comprised cells with diploid DNA while 85% of 
the grade III TCCs and 95% of invasive carcinomas comprised aneuploid cells. This study 
also showed that survival of patients with diploid tumors was significantly better than that 
of patients with aneuploid tumors. The clinical response to treatment proved to be better 
in diploid tumors (Wijkström 1990). In a study of 63 patients with primary grade 3 
Carcinoma in situ (CIS), Norming et al. (1992) found that patients with multiple aneuploid 
cell populations had a significantly higher progression rate than patients with a single 
aneuploid tumor population. However, other results were controversial and suggest a 
relatively low predictive value of DNA ploidy as prognostic marker (Herr 1989, Hug 1992, 
Giella 1992). There is a consensus on the value of tumor grade as a predictor for 
progression and survival (Cutler 1982, Heney 1983, Abel 1988). Jakse et al. (1987) suggested 
that a patient with a stage Tl, grade 3 tumor requires additional therapy to improve the 
treatment outcome because of the aggressive biological behaviour of this subpopulation 
when compared to other tumors with lower grade in the same stage. However, the 
inconsistency among pathologists (inter-observer variation) and for an individual pathologist 
(intra-observer variation) to determine tumor grade might be a problem in determining the 
clinical decision (Ooms 1983, Pannar 1989) and certainly reduces the clinical value of grade 
as prognostic factor. An association between increasing depth of bladder wall penetration 
and worse prognosis was first described by Geraghty (1922). However, it was not until 1946 
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that Jewett and Strong (1946) used depth of tumor invasion as a clinical staging system. This 
system, adopted by the UICC (1978), is now the most commonly used information to predict 
the prognosis of patients with bladder cancer. Many studies showed a significant correlation 
between tumor stage and progression (Skinner 1980, Heney 1983, Abel 1988). Tumor stage 
is so far considered to be the most important histopathological prognostic factor. 
2.4. Molecular prognostic factors. 
Loss of normal antigenic determinants or overexpression of certain antigens has been used 
to study the natural course of bladder cancer. Correlation between blood group isoantigens 
expression and tumor behaviour has been reported, however, the results were contradictory 
(Pauwels 1988). Aberrant or absent T-antigen expression, a related molecule of blood group 
antigens, in low-grade, low-stage bladder tumors correlated with high recurrence rate (Blasco 
1988). Markers for proliferative activity are considered to be important in tumor biological 
behaviour. Expression of a proliferation marker, Ki-67, is significantly related to higher 
recurrence rate (Fontana 1992). Most of these markers have limited individual diagnostic 
value (large overlap between groups). 
More recent approaches to find prognostic factors are based on the identification of 
molecular characteristics specific for aggressive tumor cells. Activation of oncogenes and 
inactivation of tumor suppressor genes are most likely etiologically related to cancer 
development. Studies on oncogenes in bladder cancer revealed that ras gene mutations occur 
infrequently in transitional cell carcinoma of the bladder (Feinberg 1983, Wood 1992). 
Recently, more attention was focused on the amplification of the c-erb B-2/iieu oncogene. 
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The c-erb B-2/neu product was more frequently expressed in high grade, high stage tumors 
(Moriyama 1991). The role oic-myc in transitional cell carcinoma of the bladder is not clear 
although increased levels of expression or alterations in the methylation oic-myc were found 
in some tumors (Masters 1988, Del-Senno 1989). The tumor suppressor gene, p53, is 
frequently mutated in high stage, high grade tumors. These findings suggest that p53 gene 
mutations are late events in bladder cancer progression which could limit its usefulness in 
predicting the treatment outcome (Sidransky 1992). However, more recently Spruck III et 
al. (1994) found that 65% of carcinoma in situ (CIS) had already p53 mutations. Growth 
factors are a class of proteins that bind to specific cell-surface receptors (GF-Rs), inducing 
a variety of responses, including mitosis, in susceptible target cells. Abnormal production, 
expression, or function of growth factors or their receptors can result in unregulated growth, 
a hallmark of malignant transformation. The Epidermal Growth Factor (EGF) is found in 
high concentrations in urine, and its receptor (EGF-R) has been found to be overexpressed 
in a significant proportion of bladder tumors (Neal 1990). Using immunohistochemistry, Neal 
et al. (1990) found that EGF-R staining significantly correlated with decreased patient 
survival, tumor progression, and tumor recurrence. Moreover, muscle invasive tumors 
showed increased EGF-R staining when compared to superficial tumors. However, Messing 
(1990) found that superficial and invasive tumors express EGF-Rs equally with no significant 
difference in the staining pattern between the two groups. Therefore the value of EGF-R 
is still under evaluation. Recent studies have shown that E-cadherin, a member of the Ca'*-
dependent cell-adhesion molecules, can play a role in invasive and metastatic behaviour. E-
cadherin is expressed in RT4 and RT112 human bladder carcinoma cell lines which are not 
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invasive, whereas the EJ24 cell line which is invasive did not show E-cadherin expression 
immunohistochemically (Frixen 1991). A more recent study on human bladder cancer by our 
group (Bringuier 1993, this thesis) found that decreased E-cadherin expression was 
significantly correlates with both increased tumor grade and stage. This study also 
demonstrated that aberrant E-cadherin immunoreactivity correlated significantly with shorter 
survival of the patients. 
Conclusions. 
Although many factors have been studied, not one of these factors showed superiority in 
predicting tumor behaviour. Using the combination of several parameters besides 
pathological grade and stage will likely increase the accuracy of the prediction of tumor 
progression. 
Knowledge of molecular characteristics associated with aggressive biological behaviour in 
prostate and bladder cancer will hopefully reveal new prognostic markers. This important 
knowledge will lead to better insight of the tumor biological potential and thus be helpful 
in treatment decision. 
Outline of the thesis. 
The aim of this study was to analyze the prognostic value of two potential molecular 
prognostic factors for bladder and prostate cancer. In order to put these data into 
perspective first a review of the available literature to date concerning prognostic markers 
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in general is presented in chapter 1. 
Herein the distinction is made between clinical, histopathological, biolochemical and 
molecular prognostic factors. The latter group was in the focus of this study. 
Prostate cancer is a complex disease and the cell biology is poorly understood. Hence, in 
order to gain better insight in the cell biological processes associated with the development 
of prostate cancer we used antibodies against cell type specific intermediate filament 
proteins, keratins (chapter 2). One of the potential molecular prognostic factors that has 
gained considerable interest is the cell adhesion molecule E-cadherin. Its value was first 
determined in the immunohistochemical analyses comparing E-cadherin 
¡mmunohistochemistry with tumor grade (chapter 3). The data indicate that E-cadherin could 
have additional value over stage and grade since within the group where grade could not 
discriminate between aggressive and non-aggressive lesions (moderately/poorly differentiated 
tumors), E-cadherin immunohistochemistry provided a tool to differentiate two groups. In 
chapter four we, therefore, confronted the immunohistochemical data with the clinical data. 
A similar study was performed on bladder cancer (chapter 5). E-cadherin expression was 
determined in an immunohistochemical study and confronted with histopathological and 
clinical data. The studies so far indicate that there is a clear potential of E-cadherin as a 
molecular prognostic factor. More recent insight indicate that even though E-cadherin is 
expressed normally, still there might be defective function due to loss of the anchoring 
protein a-catenin. In order to find out whether o-catenin had additional prognostic value we 
also did an immunohistochemical study on prostate cancer specimens (chapter 6). 
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Abstract 
The use of intermediate filaments in cancer diagnosis has gained considerable interest, not 
only because the origin of the disease can be determined (e.g., epithelial versus 
mesenchymal) but moreover because the epithelial intermediate filaments, the keratins, 
further enable differentiation on basis of their expression pattern. Previous studies, using a 
limited set of anti-keratin antibodies showed different immuno-phenotypes of non-malignant 
prostate and prostate cancer, particularly the loss of expression of keratin 14 in prostate 
cancer, which is normally expressed in basal cells. 
In this study we used a comprehensive panel of monoclonal antibodies to investigate 
expression of keratins 4, 5, 7, 8, 10, 13, 14, 16, 17, 18, 19, and keratin "basal". Monoclonal 
antibodies against vimentin and desmin, were also included in this study. These monoclonal 
antibodies were used to stain 62 human prostate cancer specimens and 21 non-malignant 
prostate specimens. We found that only expression of keratins 8, 18, 19, and keratin "basal" 
(with monoclonal antibody RCK103) were conserved during malignant transformation with 
a tendency of decreased expression in high grade tumors except for keratin 8 which 
demonstrate similar patterns in all of the tumor specimens. There was no difference in the 
staining pattern between primary tumors and those that recurred after hormonal treatment. 
Monoclonal antibodies RCK107 and E3, directed against keratins 14 and 17 respectively, 
were exclusively expressed in the basal cells and can be used to distinguish non-malignant 
prostate which has positive immunoreactivity in the basal cells, and prostate cancer in which 
no expression of these keratins can be found. In contrast with other studies, we found only 
sporadic expression of vimentin in some of the low grade tumor. 
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Introduction 
Prostate cancer, one of the most prevalent tumors among males and accounting for 13% to 
cancer related deaths [1] is diagnosed in a wide spectrum of histological appearances. 
Histologically, the neoplastic transformation is marked by a loss of the basal cell layer [2]. 
This phenomenon however, is sometimes difficult to evaluate in well differentiated lesions 
in the prostate [3, 4]. In this respect keratin immunophenotyping is particularly useful since 
basal cell specific anti-keratin antibodies (EAB903, KA1, 34BE12, and CK8.12) have been 
shown to be instrumental in distinguishing benign prostatic processes from cancer [5-8]. 
Keratins, a family of intermediate filament proteins, are a major component of the 
cytoskeleton of epithelial cells and at least 20 different keratins can be distinguished in 
human epithelia, catalogued as keratin 1 to keratin 20 by Moll et al. [9, 10]. Epithelial cells 
show different combinations of keratins depending on the cell type, and furthermore the 
expression of a certain keratin was mostly maintained after neoplastic transformation in 
many epithelial tumors [9, 11-14]. Specific combination can occur in different epithelial 
differentiation pathways. In general, an acidic keratin protein has to combine with a neutral 
to basic keratin protein to form filaments [12, 15]. Practical application of keratin 
immunohistochemistry can be used in the distinction of epithelial from non-epithelial cells 
or to identify sporadic epithelial tumor cells in a mesenchymal background [16]. 
Furthermore, monospecific keratin monoclonal antibodies recognizing one or two subtypes 
can be characteristic for a certain epithelial differentiation pathway, and may therefore 
reveal the primary site of a carcinoma [16]. 
Antibodies to specific keratin polypeptides can be used not only to differentiate between 
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prostatic basal and luminal cells but also to study the cell biological processes associated with 
prostatic carcinogenesis [17,18]. 
Vimentin is a mesenchymal subtype of Intermediate Filament Protein, and coexpression of 
vimentin and keratin has been reported in prostate tissue [19-22]. However, these results 
were controversial especially in malignant prostatic processes. 
In this present study we describe our evaluation of non-malignant and malignant prostate 
epithelial tissue for keratins, vimentin, and desmin immunoreactivity using an extensive panel 
of monoclonal antibodies specific for a single keratin or a keratin shared epitopes, vimentin 
and desmin. 
Materials and Methods 
1. Tissues 
Snap-frozen tissues of 62 human prostatic carcinoma specimens as well as 21 non-malignant 
prostate specimens were used in this investigation. Based on the clinical course, tumor 
specimens were divided into two groups: primary tumor and hormone-refractory tumor. The 
primary tumors were obtained by transurethral resection or radical prostatectomy from 43 
patients. Nineteen hormone-refractory tumor specimens were obtained by transurethral 
resection from patients who had complaints caused by locally recurrent tumor after a history 
of androgen ablation treatment (either surgical or medical). Serial tissue sections were cut 
on a cryostat at 4-6 μιπ and were stored at -20°C until use. 
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2. Histopathological grading 
One section from each serial sections for the immunohistochemical analysis was stained with 
hematoxylin and eosin to determine the histopathological grading using the Gleason score 
(GS) system [23] with GS2 being the most differentiated process and GS5 being the most 
undifferentiated malignant process. The primary tumors consisted of 11 GS2, 14 GS3, 12 
GS4, and 6 GS5, while there were 2 GS2, 3 GS3, 8 GS4, and 6 GS5 in the hormone-
refractory group. 
3. Antibodies 
Twenty-two monoclonal antibodies were used in this study as summarized in Table 1. The 
monoclonal antibody RCK103 was indicated in this study as keratin "basal" since it stains 
primarily the basal cell compartment in normal human prostate. Monoclonal antibody 
RKSE60 directed against keratin 10 was used as an internal control since the expression of 
this particular keratin is specific for keratinizing squamous cells. In the columnar epithelial 
cells, nonkeratinizing squamous cells or nonepithelial cells, no reaction was found with this 
antibody [24]. 
4. Immunohistochemistry 
The indirect immunoperoxidase technique used in this study was performed at room 
temperature. The frozen sections were fixed with acetone for 10 minutes and air dried. 
Preincubation were done with 10% normal rabbit serum in phosphate-buffered saline (PBS) 
for 30 minutes and subsequently incubated with primary antibody for 1 hour. After rinsing 
38 Chapter 2 
with PBS they were incubated with horseradish peroxidase-conjugated rabbit anti-mouse 
immunoglobulin (Dakopatts A/S, Glostrup, Denmark) diluted 1:100 in PBS containing 1% 
bovine serum albumin (BSA) for 30 minutes, and rinsed again with PBS before detection 
of the peroxidase activity with 3,3'-Diaminobenzidine 0.6 mg/ml (Sigma, St. Louis, MO) in 
0.65% Imidazol/PBS containing 25 μΐ of 30% Н
г
О
г
. Following brief rinsing with water, the 
sections were incubated with 0.5% CuS04 (in 0.9% NaCl) for 5 minutes to intensify the 
reactions. After rinsing with water, the sections were counterstained with hematoxylin, 
dehydrated and mounted. Control experiments were done with 1% BSA in PBS instead of 
primary antibody. The sections were then analyzed semiquantitatively for the fraction of cell 
staining, and the number of samples that stained with each monoclonal antibody/the total 
examined (%) was recorded. 
The fraction of staining for each samples was divided as follows: Fraction 0 refer to negative 
staining; Fraction 1, sporadic of single cell or less than 10% cells are stained; Fraction 2, 10-
50% of the cells stained; Fraction 3, 51-90% of the cells stained; and Fraction 4 more than 
90% of the cells stained. 
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Table 1: Monoclonal antibodies used in 
mAb' 
6 В 10 
AE14 
RCK 105 
M 20 
CAM 5.2 
RKSE 60 
1 C 7 
2 D 7 
LL001 
LL002 
RCK 107 
LL 0025 
E 3 
RGE53 
RCK 106 
CK 18-2 
2 C 8 
LP 2 К 
RCK 102 
RCK 103 
RV202 
RD301 
Ig Subtype 
IgGl 
IgGl 
IgGl 
IgG2a 
IgGl 
IgG2b 
IgG2a 
IgG2a 
IgG3 
IgGl 
IgGl 
IgG2b 
IgGl 
IgGl 
IgGl 
IgGl 
IgG2b 
IgGl 
IgGl 
IgGl 
IgG2b 
IFP recog 
CK 4 
CK 5 
CK 7 
CK 8 
CK 8 
CK 10 
CK 13 
CK 13 
CK 14 
CK 14 
CK 14 
CK 16 
CK 17 
CK 18 
CK 18 
CK 18 
CK 18 
CK 19 
C K 5 & 8 
CK "basal" 
Vimentin 
Desmin 
this studv 
Source 
G. van Muijen, Nijmegen, NL 
T.-T. Sun, New York, USA 
F. Ramaekers, Maastricht, NL 
G. van Muijen, Nijmegen, NL 
Becton & Dickinson 
Etten-Leur, NL 
F. Ramaekers, Maastricht, NL 
G. van Muijen, Nijmegen, NL 
G. van Muijen, Nijmegen, NL 
E. Lane, Dundee, UK 
E. Lane, Dundee, UK 
F. Ramaekers, Maastricht, NL 
E. Lane, Dundee, UK 
S. Troyanovsky, Moscow, RUS 
F. Ramaekers, Maastricht, NL 
F. Ramaekers, Maastricht, NL 
G. van Muijen, Nijmegen, NL 
E. Lane, Dundee, UK 
F. Ramaekers, Maastricht, NL 
F. Ramaekers, Maastricht, NL 
F. Ramaekers, Maastricht, NL 
F. Ramaekers, Maastricht, NL 
Ref 
25 
26 
27 
28 
29 
24 
25 
25 
30 
30 
31 
31,32 
33 
13 
27 
34 
28 
34 
27 
35,36 
27 
37 
* All were mouse monoclonal antibody's 
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RESULTS 
1. Keratin immunophenotype in non-malignant prostate tissue. 
The detailed analysis of the staining is given in Table 3, and summarized in Table 2. 
The monoclonal antibody directed against keratin 4 (6B10) partially stained (mostly 
sporadically) basal cells in 13/21 (62%) of the samples (Fig. 1A). In a few specimens (3/21, 
14%) also the luminal cells were positive, albeit that the fraction of cells that were 
immunoreactive with 6B10 was much lower than in the basal compartment (data not shown). 
AE14, an antibody against keratin 5 stained specifically the basal cells. Between 10% to 90% 
of basal cells were stained in 20/21 (95%) non-malignant prostatic acini, whereas no staining 
in the luminal cells can be found (Fig. IB). 
Immunoreactivity to keratin 7 (RCK105) was found in both basal (20/21, 95%) and luminal 
cells (16/21, 76%) of the secretory acini. However, the fraction of basal cells staining tended 
to be higher, and varied from 51% to complete, whereas the fraction of luminal cells that 
were positive was between sporadic to 50% (Fig. 1С). 
Two monoclonal antibodies against keratin 8 were used in this study (M20, CAM5.2) and 
both gave similar results. All of the basal and luminal cells expressed keratin 8 (Fig. ID). It 
should be noted, however, that some of the basal cells did not stain when mAb M20 was 
used. 
Two antibodies against keratin 13 were used, 1C7 and 2D7, and both the number of the 
samples that was positive as well as the fraction of immunopositive cells was higher using 
2D7. The staining was primarily basal (Fig. IE), even though some samples were completely 
devoid of immunoreactivity (14%). In 52% of cases also the luminal stained, albeit 
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sporadically. 
Three monoclonal antibodies recognizing keratin 14 were used in this study. Monoclonal 
antibodies LL001 and LL002 gave similar results, hence these were combined in the table 
(Table 2). Monoclonal antibodies to keratin 14 stained exclusively the basal cells in all of the 
tissue samples with marked variation in the fraction of cells stained. The staining pattern of 
RCK107 was similar to that of LL001 and LL002, i.e., basal cells specific, yet RCK107 
stained a higher fraction of basal cells than LL001 or LL002 (Fig. IF). The staining pattern 
of RCK107 was similar, i.e., basal cell specific. 
Also, E3, anti keratin 17 had a similar pattern as RCK107 i.e., only basal cells stained in 
all of the tissue samples. Even more, the fraction of cells positive was higher, 13 of 21 (62%) 
tissue samples demonstrated complete staining of the basal cells (Fig. IG). 
Immunoreactivity for keratin "basal" (RCK103) was found in both basal and luminal cells of 
the acini. Almost all samples are completely immunopositive for basal cells in contrast to 
only 86% in which a much lower fraction (sporadic to 50%) luminal cells stained (Fig. IH). 
Four monoclonal antibodies against keratin 18 (RGE53, RCK106, CK18-2, and 2C8) were 
used in this study. Monoclonal antibodies CK18-2 and RCK106 gave similar results and were 
pooled in the table. All of these monoclonal antibodies stained luminal cells and some 
sporadic staining in basal cells except monoclonal antibody 2C8 that showed no staining in 
the basal cells. Only 57% of the samples show complete staining using 2C8 in the luminal 
cells (Fig. II). Whereas complete staining of the luminal cells was found in 20/21 (95%) of 
samples using either RGE53, RCK106 or CK18-2 (Fig. 1J). 
Keratin 19 (LP2K.) was expressed in basal cells as well as luminal cells in all of the tissue 
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samples (Fig. IK). The fraction of basal cells that were stained was higher than that of the 
luminal cells i.e., 16/21 (75%) samples show more than 51% immunopositive fraction in the 
luminal compartment. 
RCK 102 recognizing both keratins 5 and 8 stained, as expected from the above results, all 
epithelial cells of the secretory acini (Fig. IL). 
Monoclonal antibodies against keratin 10 and 16 showed no staining in any of the samples. 
Table 2: Keratin staining in non-malignant prostate tissue (n= 21). 
Keratin 
4 
5 
7 
S 
13 
14 
17 
18 
19 
5&8 
"basal" 
Basal cells 
о 
О 
О 
OO 
О 
OO 
OO 
о 
OO 
OO* 
OO 
Luminal cells 
о 
О 
OO 
0 
OO 
OO 
OO* 
о 
о : <50% samples stained; staining fraction <50% 
О : >50% samples stained; staining fraction <50% 
OO : >50% samples stained; staining fraction >50% 
* : Complete staining in all samples. 
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2. Vimentin and Desmin expression in non-malignant prostate tissue. 
Anti-Vimentin (RV202) partially stained the stromal component and interestingly also 
luminal cells in 16/21 (76%) of the tissue samples varying from sporadic to complete 
staining (Fig. IM). Desmin was expressed exclusively in the stromal part of the tissues 
(data not shown). 
3. Keratin expression profile in prostatic carcinoma. (Table 4). 
Only 5 antibodies (against keratins 8,18,19, 5&8, and "basal") are immunoreactive in the 
tumor specimens analyzed. Some differences in relation to tumor grade are evident. 
Keratin 8 is expressed in all of the GS2 and GS3 tumor cells using monoclonal antibodies 
M20 and CAM5.2 (Fig. 2A), hence shows as in non-malignant prostatic acini a 
panreactive pattern. However, two cases (10%) in GS4 and 1 case (8%) in GS5 showed 
less than 90% staining of the tumor cells (Fig. 2B). 
Keratin 5 was not expressed in cancer hence expectedly RCK102 stained all of the GS2 
and GS3 tumor cells (Fig. 2C). As with M20 and CAM5.2, in the GS4 and 5 group, one 
sample (5%) showed less than 90% staining with RCK102 in the tumor cells (Fig. 2D) 
while the others resulted in complete staining. 
Monoclonal antibodies RGE53, RCK106 and CK18-2 showed similar staining patterns, 
i.e. all of the tumor cells in GS2 and GS3 were immunoreactive (Fig. 2E). In GS4 and 
GS5, some of the tumor cells showed less than 90% staining. However, monoclonal 
antibody 2C8 showed also less tumor cells staining in the more undifferentiated tumor 
(e.g. only 50% of GS4 and 42% of GS5 tumor showed complete staining) (Fig. 2F). 
Keratin 19 was expressed in more tumor cells in GS2 and GS3 (Fig. 2G) when compared 
to high grade tumors. In GS5, no samples showed complete staining using monoclonal 
antibody LP2K (Fig. 2H). 
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Expression of keratin "basal" could be demonstrated in all of the tumor examined in this 
study although there was a trend of decreased percentage of immunopositive cells in high 
grade tumors. No tumor samples expressed complete staining with monoclonal antibody 
to this keratin (Fig. 2I,J). In GS5 tumors, 75% of samples were not immunoreactive with 
monoclonal antibody RCK103. 
4. Vimentin expression in prostatic carcinoma. 
Four of 13 cases (31%) in GS2 and 1 of 17 cases (6%) in GS3 tumor showed sporadic 
expression of vimentin (Fig. 2K) while no staining could be found in GS4 and GS5 
tumors (data not shown). 
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Discussion 
The keratin immunophenotype in epithelial cells is dependent on cell type, pathological 
status, and cellular differentiation. These characteristics make anti-keratin antibodies 
useful tools as differentiation markers for diagnosis [15]. The epithelial cells in prostatic 
secretory acini can be topologically differentiated in luminal and basal cells. Previous 
studies using antibodies directed against keratins could discriminate these two cell layers 
[5,6,21,36,38]. However, recently we identified a subpopulation of cells which showed a 
keratin expression profile intermediate between those of luminal and basal cells [18]. The 
cells with this immunophenotype (keratin 14 negative, RCK103 positive, and cytokeratin 
18 positive or negative) were considered to be a good candidate for the amplifying cells 
in the still hypothetical stem cell model for the prostate [39]. Cells with this phenotype 
were also found in prostate cancer, and this was in fact the first indication for the 
presence of basal cell phenotypical characteristics in human prostate cancer. In this study 
we use a comprehensive panel of monoclonal antibodies directed against various keratins 
in order to get a more or less complete phenotype in non-malignant and malignant 
prostate tissues. 
In non-malignant prostatic acini at least nine keratin subtypes are expressed in either a 
panreactive, or in more topologically restricted patterns (for summary, see Table 3). 
RCK102 is a typical panreactive anti-keratin antibody. Other keratins like keratins 7, 8, 
and 19 were also expressed in both of the epithelial layers however, with various 
immunoreactivity as has been reported earlier [19,27,40]. The reactivity using RCK102 
tended to decrease in the high grade tumors (100% to 92%). It is not yet clear whether 
this is due to poor antigen preservation or to the loss of epithelial differentiation. The 
loss of epithelial differentiation is marked by a decrease in E-cadherin expresssion which 
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is indeed found in high grade prostate cancer [41]. The basal cells can be discriminated 
from the luminal cells using antibodies against keratin 5, 14 and 17. Antibodies RCK107 
and E3 seem to be the most reliable ones to use. The molecular basis for this is yet 
unknown, but it could be associated with abundance of the antigen or the affinity of the 
antibody for different epitopes. Four different antibodies were used to detect keratin 18 
and we found a discrepancy in the fraction of immunoreactivity and the number of 
samples that were positive between monoclonal antibody 2C8 versus RGE53, RCK106 
and CK18-2. Less samples show complete staining in the luminal cells using 2C8 whereas 
almost all samples show complete luminal cells staining with the other monoclonal 
antibodies as had been reported earlier [28,29,42]. 
The expression of vimentin is interesting in that a highly variable fraction of cells in the 
non-malignant acini cells were stained. The stromal compartment primarily expresses 
desmin, presumably due to the high content of smooth muscle cells. 
In the malignant prostate specimens we confirmed various earlier observation that the 
pure basal cell type restricted keratins (keratins 5, 14, and 17) are not anymore 
expressed, which is clearly in good concordance with the observation that the basal cell 
layer is lost [5-8]. Indeed luminal keratins 8 and 18 are usually homogenously expressed 
in the malignant specimens. However, our earlier observations that basal cell type keratin 
immunoreactivity is found in prostate cancers using RCK103 [18], a rather undefined 
antibody, was now also confirmed using anti-keratin 19. Immunoreactivity using both 
antibodies decreased with increasing tumor grade. 
The keratin immunophenotype in prostate cancer indicates a predominant luminal 
keratin profile with definite basal cell characteristics (keratin 19 and RCK103). In the 
stem cell model this would fit well with an amplifying cell phenotype. Moreover, the 
Keratin and vimentin expression in prostate epithelial tissues 49 
keratin 19 antibody could be an additional marker (to RCK103) for this subpopulation 
of cells. 
Only a small number of the prostate cancer specimens demonstrated sporadic vimentin 
expression. Previous studies were controversial on vimentin expression in prostate cancer, 
and this discrepancy could be caused by different monoclonal antibody used in these 
studies or loss of antigen during processing [19-22,38,43]. 
The tendency towards a slight decrease in keratin expression with increasing grade, is 
therefore not accompanied by an increased vimentin immunoreactivity. The keratin 
immunophenotype here presented is based on an extensive panel of antibodies. We have 
shown that prostatic carcinomas express keratins 8, 18 and 19, and that the fraction of 
keratin 19 positivity decreases with increasing tumor grade. The presence of basal cell 
characteristics in the low and intermediate grade tumors indicates that a cell type that 
can be placed in the stem cell kinetics hierarchically in between the basal and luminal cell 
is the target for neoplastic transformation. 
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Legends 
Figure 1. 
Immunoperoxidase staining patterns in frozen section of non-malignant prostate tissues. 
A: Sporadically expression of keratin 4 in basal cells with monoclonal antibody (mAb) 6B10; 
B: Immunohistochcmical staining with mAb AE14 directed against keratin 5, stained specifically the basal 
cells; 
C: Expression of the basal as well as the luminal cells using mAb RCK105, specifically directed against 
keratin 7. Note that most of the basal cells were stained whereas only sporadic staining was found in 
the luminal cells (arrow head); 
D: Expression of keratin 8 in all of the basal as well as luminal cells using mAb CAM5.2; 
E: Staining pattern of keratin 13 which is primarily in the basal cells using mAb 2D7; 
F: High staining fraction (51-90%) of keratin 14 in basal cells using mAb RCK107; 
G: Keratin 17 was demonstrated only in the basal cells using mAb E3; 
H: Monoclonal antibody RCK103 showed complete immunorcactivity in the basal cells; 
I: Expression of keratin 18 using mAb 2C8 which showed no staining in the basal cells and incomplete 
immunoreactivity in luminal cells; 
J: Complete expression of keratin 18 in the luminal cells using mAb RCK106; 
K: Keratin 19 was expressed in both basal and luminal cells using mAb LP2K; 
L: Expression of keratin S & 8 in all of the basal and luminal cells using mAb RCK102; 
M: Vimentin was expressed particularly in the stromal component and in some of the luminal cells (arrow 
head). 
Figure 2. 
Immunoperoxidase staining patterns in frozen section of prostate cancer specimens. 
A: Complete expression of keratin 8 in GS 2 tumor. Monoclonal antibody (mAb) M20 and CAMS.2 show 
similar results; 
B: Less than 90% staining of keratin 8 in tumor cells of GSS prostate cancer (mAb M20 abd CAMS.2 
show similar results); 
C: Complete expression of keratin S&8 in GS 2 tumor cells using mAb RCK102; 
D: Less than 90% staining of keratin 5&8 in GSS tumor using mAb RCK102; 
E: Monoclonal antibody RCK106 showed complete expression of keratin 18 in all of the tumor cells in 
GS3 tumor (similar results were also found using mAb RGE53 and CK18-2); 
F: Less staining fraction in GS5 tumor using mAb 2C8; 
G: Complete expression of keratin 19 in GS2 tumor with mAb LP2K; 
H: Incomplete expression of keratin 19 in GS5 tumor with mAb LP2K; 
I: Incomplete expression of keratin "basal" in GS3 tumor using mAb RCK103; 
J: Incomplete expression of keratin "basal" in GSS tumor using mAb RCK103; 
K: Some expression of vimenlin in GS2 tumor (arrow head). 
Magnifications: x400. 
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Abstract 
E-cadherin is a Ca2+-dependent cell adhesion molecule which plays an important role 
in normal growth and development via mediation of homotypic, homophilic cell-cell 
interaction. Recent studies suggest that E-cadherin may be important in neoplastic 
progression as well, particularly as a suppressor of invasion. We have previously 
demonstrated that the invasive phenotype of rat prostate cancer cells is associated with 
decreased expression of E-cadherin (Bussemakers, M.J.G., Van Moorselaar, R.J.A., 
Giroldi, L.A., Ichikawa, T., Isaacs, J.T., Debruyne, F.M.J., and Schalken, J.A. Cancer Res. 
52:2916-2922, 1992.). This is of particular interest since the locus to which the human E-
cadherin gene is mapped is frequently involved in allelic loss in prostate cancer (Carter, 
B.S., Ewing, СМ., Ward, W.S., Treiger, B.F., Aalders, T.W., Schalken, J.A., Epstein, J.I., 
and Isaacs, W.B. Proc. Natl. Acad. Sci. USA 87:8751-8755, 1990 & Bergerheim, U.S., 
Kunimi, K., Collins, V.P., and Ekman, P. Genes, Chromosomes & Cancer, 3: 215-220, 
1991.) Impaired E-cadherin function is likely to be associated with aberrant expression 
of the protein. We therefore analyzed E-cadherin expression in situ by 
immunohistochemistry in non malignant and malignant specimens of human prostatic 
tissue. Of 92 tumor samples of either primary or metastatic deposits of prostate cancer, 
46 had reduced or absent E-cadherin staining when compared to non-malignant prostate 
which uniformly stained strongly positive. There was a statistically significant correlation 
between decreased expression of E-cadherin and loss of tumor differentiation. 
Additionally, certain tumors within a histologically similar group could be distinguished 
by the presence of mixed populations of E-cadherin negative and positive cells. The 
percentage of tumors with aberrant E-cadherin staining increased when clinically localized 
tumors were compared to either tumors with extensive local progression or metastatic 
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deposits of prostate cancer suggesting a correlation between loss of E-cadherin and 
tumor progression. Taken together, these findings suggest that further exploration of E-
cadherin as a candidate invasion suppressor molecule in human prostate cancer is 
warranted. 
Introduction 
The clinical course of men with prostate cancer may vary widely, even in men whose 
tumors are of similar clinical stage and histological grade. At present there is no reliable 
way to predict which men with prostate cancer will progress and eventually die of their 
disease. Current systems of staging and grading prostate cancers provide adequate 
predictive value for tumors at either end of the differentiation spectrum (i.e. well and 
poorly differentiated), but are particularly deficient at predicting outcome of patients 
whose tumors lie in between these two extremes (1,2). Unfortunately this latter class of 
prostate cancers is the most common (2). To address this problem, we have begun to 
analyze molecular genetic alterations in prostate cancer with the goal of identifying 
changes which may be of predictive value. In a previous study of primary prostate 
cancers (3), chromosome 16q was the most frequent location of allelic loss, suggesting 
this chromosomal arm as the possible site of a tumor suppressor gene which becomes 
inactivated in this disease. A subsequent study by Bergerheim et al. also found frequent 
allelic loss on chromosome 16q in both primary and metastatic deposits of prostate 
cancer (4). Interestingly, recent studies of breast cancer, hepatocellular carcinoma, and 
Wilms' tumors have also observed frequent loss of alleles from chromosme 16q (5-7). 
Multiple genes are known to reside in the region of chromosome 16q commonly deleted 
in prostate cancer (4). Of particular interest is E-cadherin, a cell adhesion molecule 
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which has been shown to have characteristics of a suppressor of invasive phenotype 
(8-12). To assess the possible relevance of changes in E-cadherin to prostate cancer, we 
examined the expression of E-cadherin in both normal and malignant prostate tissue. 
Cadherins are cell surface glycoproteins involved in homotypic Ca2+-dependent cell-cell 
adhesion (13). These molecules play an essential role in embryonic development and 
morphogenesis, and in maintenance of the normal structure and function of adult tissues 
(14, 15). More than ten subclasses of Cadherins have been identified (16-21). Three of 
them, E-, N- and P-cadherin, share a common basic structure and mediate cell-cell 
binding in a homophilic and subclass specific manner (22). E-cadherin is also called 
uvomorulin (23), L-CAM (24), cell-CAM 120/80 (25) or Arc-1 (26). Its expression is 
restricted to epithelial tissues (27, 28). Considering the important guiding role of E-
cadherin in normal development, various authors suggested that impaired function of this 
molecule could be important in the acquisition of invasive potential (8, 9, 22). Indeed, 
Behrens et al. (10) showed that the Madin-Darby canine kidney (MDCK) cells which 
form tight epithelial monolayers, acquired the ability to invade collagen gels and 
embryonal heart tissue when their intercellular adhesion is inhibited by addition of anti-E-
cadherin antibodies. Similarly, in a study on a variety of human cancer cell lines, Frixen 
et al. (11) found that non-invasive cell lines expressed E-cadherin protein, whereas 
invasive carcinoma cell lines had lost E-cadherin expression. Moreover, this study 
showed that by transfection with E-cadherin cDNA, the invasive phenotype could be 
suppressed. From the study of these model systems it has become clear that there is a 
functional relation between the invasive phenotype and decreased expression of E-
cadherin. Various studies now suggest that a similar correlation exists in some primary 
human cancers; recent reports show that a highly undifferentiated liver carcinoma lacked 
Expression of Ε-Cadherin in high grade prostate cancer 63 
E-cadherin expression (29) as do poorly differentiated squamous cell carcinomas of the 
head and neck (30). For prostate cancer, studies of E-cadherin expression are 
particularly relevant, since, as mentioned above, the gene for this protein is located on 
a chromosomal segment which is frequently lost in prostate cancer development (3,4). 
In a previous study of the Dunning R-3327 rat prostatic cancer model system, expression 
of E-cadherin mRNA was found in the well and poorly differentiated lines with low 
invasive potential, while all established lines with high invasive potential had no 
detectable levels of E-cadherin transcripts. Similar findings are found at the protein level. 
In tumor lines derived from a de novo arisen metastatic subline, E-cadherin expression 
was also decreased (31). To investigate the role of E-cadherin in human prostate cancer 
development, we used immunohistochemical staining to evaluate the expression of E-
cadherin in surgical specimens of normal prostate and malignant prostate tissue with 
varying levels of differentiation. 
Materials and methods 
Surgical Specimens. We used snap frozen tissues of 84 human prostatic carcinoma 
specimens as well as 7 metastatic lesions in lymph nodes and 1 in testis. Of the 84 
primary tumors, 47 were radical prostatectomy specimens (clinically localized cancers), 
and 37 were obtained at transurethral resection (tumors with extensive local progression). 
Twenty three non-malignant prostate specimens obtained from either cysto-prostatectomy 
or radical prostatectomy were also included. All of these tissues were obtained at the 
time of surgery. Serial sections from the frozen tissues were cut on a cryostat at 4-6 mm 
and air dried. The sections were stored at -20°C until use. 
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Primary tumors 
Gleason Grade 
4 
5 
6 
7 
8 
9 
10 
Overall 
Metastatic lesions 
positive 
8 (100) 
4(100) 
13 (87) 
11 (79) 
8(31) 
44 (52) 
2(25) 
heterogenous 
2(13) 
3(21) 
13 (50) 
4(50) 
5(55) 
27 (32) 
5(62) 
negative 
5(19) 
4(50) 
4(45) 
13 (16) 
1(12) 
total 
8 
4 
15 
14 
26 
8 
9 
84 
8 
1. Antibodies. 
L-CAM (Uvomorulin) monoclonal (Euro-diagnostics BV, The Netherlands), a 
monoclonal antibody against E-cadherin was used for immunohistochemical staining. In 
addition, some sections were stained with another monoclonal antibody against E-
cadherin, HECD-1 (20) (a kind gift from Dr. S. Hirohashi, Tokyo, Japan), which gave 
equivalent results. 
2. Immunohistochemistry. 
Immunohistochemistry was performed at room temperature. The sections were fixed with 
acetone for 10 minutes and air dried. Preincubations were done with normal rabbit serum 
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diluted 1:10 with PBS for 30 minutes. They were subsequently incubated with primary 
antibody diluted 1:10 for 1 h. After rinsing with PBS they were incubated with rabbit anti-
mouse IgG peroxidase (Dakopatts A/S, Denmark) diluted 1:100 for 30 minutes, and 
rinsed again with PBS before incubation with diaminobenzidine 0.6 mg/ml in 0.65% 
Imidazol/PBS containing 0.03% H202 for 5 minutes. Following brief rinsing with water, 
sections were incubated with 0.5% CuS04 (in 0.9% NaCl) for 5 minutes. After being 
rinsed briefly with water, the sections were counterstained with hematoxylin, dehydrated 
and mounted. Primary antibody and rabbit anti-mouse IgG peroxidase were diluted with 
1% BSA/PBS*. Negative control reactions were done by incubation of the sections with 
1% BSA/PBS. E-cadherin staining patterns were scored as either uniformly positive, 
uniformly negative, or heterogeneous (mixed populations of positive and negative cells) 
as described by Schipper et al. (30). 
3. Histopathological grading. 
One section from each series for the immunohistochemical analysis was stained with 
hematoxylin and eosin to determine the histopathological grading using the Gleason score 
(32). The tumor specimens ranged from Gleason score 4 to 10 (with score 4 tumors being 
the most well differentiated of the group, and score 10 being the most poorly 
differentiated) while two of the metastatic tissues were scored as Gleason score 4, and 
six as Gleason score 8. 
*The abbreviations used are: PBS, phosphate-buffered saline; BSA, bovine serum 
albumin. 
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Results 
1. Expression of E-cadherin in non-malignant prostate. 
Twenty three samples of non malignant prostatic tissue were examined for E-cadherin 
expression immunohistochemically. E-cadherin was strongly expressed in all epithelial 
cells of all samples. The staining was localized on the membrane, particularly at areas of 
cell-cell contact (Fig.l). 
Fig. 1. Immunohistochemical detection of E-cadherin expression in non malignant prostate tissue using 
ami E-cadherin monoclonal antibody (400x). Note uniform, positive staining at each cell-cell border. 
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2. Expression of E-cadherin in prostatic carcinoma. 
Sections from 84 prostatic carcinomas were stained with monoclonal antibodies to E-
cadherin. Forty seven of these tumors were radical prostatectomy specimens obtained 
from men with clinically localized disease, and 37 were from men with extensive local 
disease who underwent transurethral resection. The degree of tumor differentiation 
(Gleason score) of these tumors ranged from well differentiated (Gleason score 4) to 
undifferentiated (Gleason score 10) (for distribution, see Table 1). Three staining 
patterns were observed in the tumor samples: uniformly positive, uniformly negative, and 
a third pattern of heterogeneous staining similar to that described by Schipper et al. in 
squamous cell carcinomas (30). In the heterogeneous pattern, a mixed population of E-
cadherin positive and negative cells was observed. As is seen in Table 1, in the most 
differentiated cancers (Gleason scores 4-5), E-cadherin was strongly and uniformly 
positive in all tumors at the cell-cell boundaries. The staining pattern and intensity were 
similar to those observed in non malignant prostatic tissue. However, in less well-
differentiated to poorly differentiated tumors (Gleason scores 6-10), we observed a trend 
of increasing percentage of tumors with heterogeneous or absent staining for E-cadherin. 
Specifically, in moderately differentiated tumors (Gleason score 6 and 7), most continued 
to exhibit the normal pattern of E-cadherin staining; however, 5 of 29 (17%) of these 
tumors exhibited heterogeneous staining (Fig. 2). In contrast, the majority (69%) of 
moderate to poorly differentiated tumors (Gleason score 8) and all of poorly 
differentiated and undifferentiated tumors (Gleason scores 9 and 10) had decreased E-
cadherin expression. Substantial fractions of tumor samples in these latter groups were 
completely devoid of E-cadherin staining (19%, 50%, and 45% of Gleason scores 8, 9, 
and 10 tumors, respectively). Overall, 52% of all tumors analyzed had uniform positive 
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staining, 16% had absent staining, and 32% had heterogeneous staining. The decreasing 
expression of E-cadherin with increasing Gleason score is highly statistically significant 
by chi-square analysis (x2= 50.157, 12 df, Ρ < 0.001). 
3. Expression of E-cadherin in prostate салсег metastases. 
Since metastatic lesions of prostate cancer are rarely surgically resected, we were able 
to obtain only a limited number of these specimens for analysis. Six of eight prostate 
cancer metastases showed either negative or heterogeneous staining with anti-E-cadherin 
antibodies (Table 1; Fig.2, I and J). Those with heterogeneous staining showed a low 
intensity, diffuse staining pattern in which the cell borders were only barely marked. Two 
metastatic deposits consisted of well differentiated prostatic adenocarcinoma cells which 
stained strongly for E-cadherin. 
A correlation between decreased E-cadherin expression and tumor progression is 
suggested when clinically localized tumors are compared to either more extensive primary 
tumors (transurethral resection specimens) or metastatic deposits of prostate cancer. 
Forty percent (19/47), 57% (21/37), and 75% (6/8) of the tumors in these three groups, 
respectively, showed reduced or absent E-cadherin staining. 
Fig. 2. Immunohistochemical detection of E-cadherin expression in prostate cancer (A -
H) and metastatic tissue (I - J) using anti L-CAM (Uvomorulin) monoclonal antibody. 
A, B: Gleason grade 4 tumor (200x,400x), and C, D: Gleason grade 5 tumor (200x,400x) 
showing positive and homogeneous staining. E: Heterogeneous staining, and F: Negative 
staining of the Gleason grade 8 tumor (400x). G: Heterogeneous staining, and H: 
Negative staining of the Gleason grade 10 tumor (400x). I: Metastatic deposit in lymph 
node consisted of moderately differentiated prostatic adenocarcinoma cells showing 
heterogeneous staining (400x) .J: Metastatic deposit in testis consisted of moderately 
differentiated prostatic adenocarcinoma cells showing heterogeneous staining (400x). 
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4. Expression of E-cadherin in prostate cancers with chromosome 16q deletions. 
In a previous study (3) we identified six primary prostatic tumors in which the majority 
of cancer cells had lost alleles from the long arm of chromosome 16. Since the E-
cadherin gene is located on this chromosomal arm, we examined the expression of this 
gene by staining sections from these tumors with anti- E-cadherin antibodies. These 
tumors had Gleason scores ranging from 6 to 9. Interestingly, five of these six tumors 
showed altered E-cadherin staining, with four showing heterogeneous staining and one 
having absent staining (Fig. 3). 
Fig. 3. Immunohistochcmical detection of E-cadhcrin expression in prostate cancers with chromosome 
16q allelic loss. Α,Β: Two tumors with chromosome 16q allelic loss showing heterogeneous staining for 
E-cadherin (400x). Note that staining, if present, is abnormally localized, particularly in tumor panel B. 
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Discussion 
E-cadherin has been demonstrated to play an important role in normal growth and 
development. Alternatively, when deregulated, it can contribute to the invasive potential 
of transformed cells, and can therefore be considered as an invasion suppressor gene (8, 
9, 22). Moreover, the fact that locus to which the E-cadherin gene is mapped (16q22.1) 
is frequently involved in allelic loss in prostate cancers (3, 4,12) prompted us to examine 
the expression of E-cadherin in non malignant and malignant human prostate tissues. 
Reasoning that loss of invasive suppressor function is likely to be associated with loss or 
aberrant expression of the E-cadherin protein we evaluated this immunohistochemically. 
We found that all of the non-malignant prostatic tissues stained positively. Similarly, all 
of the well-differentiated (Gleason score 4) and most (85%) of the moderately-
differentiated (Gleason score 5-7) prostate cancers stained with similar intensity as in non 
malignant prostatic tissue. Mixed populations of E-cadherin positive and negative cells 
were observed in the remaining moderately-differentiated tumors and in half of the 
poorly-differentiated (Gleason score 8 and 9) and undifferentiated (Gleason score 10) 
prostatic tumors. The remainder of Gleason score 9 and 10 tumors were devoid of 
staining with anti-E-cadherin antibodies. 
Several considerations indicate that a mixed or heterogeneously composed tumor may 
have increased invasive potential. Mareel et al. (8) showed that when ras transfected 
MDCK cells, which were not invasive in vitro, were injected into nude mice, they produce 
invasive and metastatic tumors. These tumors were heterogeneous in E-cadherin 
expression. Both E-cadherin-positive, well-differentiated epithelial structures and E-
cadherin-negative, undifferentiated areas were present. It was also shown by Hashimoto 
et al. (33) that highly metastatic ovarian tumor cell lines contained both E-cadherin 
positive and E-cadherin negative cells. In the high grade prostate cancers examined here, 
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we never found a normal staining pattern, i.e., tumors were either heterogeneous or 
negative for E-cadherin. None of the Gleason score 9 and 10 tumors had strong 
expression of E-cadherin. From this we can conclude that as in the Dunning R 3327 rat 
prostatic cancer model system (31), and several other human cancers (29, 30), E-cadherin 
expression is decreased in high grade malignant lesions of the prostate. Six of the 
metastatic deposits, which are poorly-differentiated, showed heterogeneous or absent E-
cadherin expression while the two well-differentiated metastases stained homogeneously 
positive. This indicates that either other mechanisms can overcome the invasive 
suppressor function of E-cadherin (34), or that E-cadherin can be temporarily down 
regulated, resulting in transient expression of the invasive phenotype. Evidence from the 
Dunning rat prostate tumor system supports this latter possibility as Bussemakers et al. 
(31) found E-cadherin positive prostate cancer cells in some metastatic lung deposits 
derived from anaplastic E-cadherin-negative primary tumor cells. The mechanisms that 
lead to aberrant expression of E-cadherin are still unclear. Obviously, it is tempting to 
speculate that loss of heterozygosity of 16q22 is one of the steps associated with loss of 
suppressive function. Classical tumor suppressor gene theories (35) then would predict 
that the remaining allele is mutated, thus abolishing complete functioning of E-cadherin. 
Alternatively, the reduced dosage of the gene due to allelic loss may result in reduced 
expression of E-cadherin to a level below a critical threshold, which by itself could be 
sufficient to impair functioning of E-cadherin. Evidence for this possibility comes from 
the study of Vleminickx et al. (9) who showed that a reduction, not elimination, of E-
cadherin expression was sufficient to induce invasiveness of kidney carcinoma cells. In the 
study presented here, we examined a limited number of prostatic tumors previously 
identified as having allelic loss of sequences on chromosome 16q. Interestingly, over 80% 
(5/6) of these primary tumors showed either heterogeneous or absent E-cadherin staining, 
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suggesting a possible causative link between these two alterations. These observations 
provide a rationale for a more extensive search for possible genetic alterations (e.g. point 
mutations, deletions) in both the coding and regulatory regions of the E-cadherin gene 
which may lead to inactivation of E-cadherin function. In addition, further studies will 
be necessary to more precisely quantitate the degree of E-cadherin down regulation and 
to determine whether a reduced level of the normal protein alone is sufficient to induce 
invasive behavior in experimental models of prostate cancer. With respect to the clinical 
value of these findings it is of particular interest to note that within the groups of patients 
with moderately-differentiated tumors, comprising the majority of cases observed 
clinically, a discrimination could be made between normally staining and aberrantly (i.e., 
heterogeneous and negative) staining tumors. Due to the long follow up necessary, it is 
not yet clear whether these findings have predictive value for clinical course in terms of 
survival. It is therefore important that antibodies be developed that can be used on 
archival material in order to test the prognostic value of E-cadherin staining 
retrospectively. On the other hand preliminary data on the relation between decreased 
E-cadherin expression and shortened survival in bladder tumors (P.P. Bringuier, personal 
communication) indicate the potential of this marker. We suggest that the value of 
decreased E-cadherin expression in prostate cancer be tested prospectively on a large 
scale. 
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Abstract 
Decreased levels of the cell-cell adhesion molecule E-cadherin are associated with loss 
of differentiation in a number of human carcinomas. However, the value of E-cadherin 
as a prognostic marker in these cancers is largely undetermined. A previous study of E-
cadherin levels in prostate cancer revealed that almost 50% of tumors examined had 
reduced or absent levels of this protein (Umbas et al. Cancer Res., 52: 5104). To 
determine potential prognostic significance of this finding, prostate cancers specimens 
from 89 patients were evaluated immunohistochemically for E-cadherin expression, and 
the results related to histopathological grade, tumor stage, presence of metastases, and 
survival. 
As previously observed, a significant inverse correlation was found between E-cadherin 
expression and tumor grade. Importantly, we also found significant correlations between 
E-cadherin expression and tumor stage and overall survival. Sixty-three per cent of the 
tumors that extended beyond the prostate capsule (T3-4) versus 33% of the tumors 
confined to the prostate (Tl-2) had aberrant expression (chi-square=8.1, p<0.005). 
Seventy-six per cent of the primary tumors from patients that presented with metastases 
showed aberrant staining compared to 32% from patients without metastases (chi-
square= 14.9, p<0.001). The life table analysis showed a significantly higher survival rate 
for patients with normal staining compared to patients with aberrant expression (log rank 
test: chi-square= 20.4, p<0.001). Moreover, abnormal expression of E-cadherin 
correlated significantly with progression after radical prostatectomy (p < 0.005). Tliese 
results suggest that E-cadherin expression can serve as prognostic indicator for the biological 
potential of prostate cancer. 
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Introduction 
Prostate cancer is one of the most common malignancies in men (1) and most patients 
will succumb to their disease once it has metastasized. Improvements in the diagnosis of 
prostate cancer have now resulted in screening programs that reveal many more organ 
confined lesions, with a concomitant increase in the number of radical surgeries. Whether 
this truly improves overall survival is not clear because of the unpredictable biological 
potential of these tumors. Not every prostate cancer will progress (2,3), and on the other 
hand, metastasis still develop in a considerable group of patients with localized disease 
that are treated radically (4). The value of grade and clinical stage of the disease is 
controversial (5,6), even though the pathological stage seems to be one of the best 
prognostic factors available to date (7). Clearly, methods that allow more accurate 
prediction of the clinical behaviour are urgently needed. 
In this respect the identification of molecular prognostic markers has now gained 
considerable attention, albeit that few of these have yet established clinical value. One 
of these markers, the epithelial cell adhesion molecule, E-cadherin, is of particular 
interest since it can function as invasion suppressor gene (8-10). In normal physiological 
conditions, E-cadherin plays an important role in embryonic development, 
morphogenesis and maintenance of epithelial integrity (11). Furthermore, loss of E-
cadherin expression correlated well with the in vitro invasive phenotype of cancer cell 
lines (12,13). Also, in human cancers E-cadherin expression correlated inversely with 
tumor grade. Recently we demonstrated a statistically significant correlation between 
abenant expression of E-cadherin and increased grade of human prostate cancer. The 
staining pattern and intensity of all the well differentiated tumors (Gleason score 4 and 
5) were uniformly positive, while all of the poorly differentiated and undifferentiated 
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tumors (Gleason score 9 and 10) had aberrant E-cadherin expression (14) comprising 
either heterogeneous or negative patterns. It is not yet clear whether aberrant E-cadherin 
immunoreactivity has predictive value for the clinical course in patients with carcinoma 
of the prostate. In the present study we evaluated the prognostic value of E-cadherin 
expression in addition to tumor grade and stage in 89 patients with prostate cancer. 
Materials and methods 
1. Patients 
Eighty-nine prostate cancer patients, treated between January 1987 and December 1991, 
were included in this study. The mean age at the time of diagnosis was 70 years (range: 
42 to 87 years). Clinical tumor staging was done by digital rectal examination and 
transrectal ultrasound. Pathological staging was determined according to the classification 
of the International Union Against Cancer (15). Bone scan was performed in order to 
detect metastatic lesions and further evaluation by radiographs was done in case of a 
positive bone scan. The treatment options were radical prostatectomy for early stage and 
hormonal therapy, either medical or surgical, for advanced disease. Only in 4 cases 
external beam radiotherapy with linear acceleration was given in combination with 
hormonal treatment. The patient characteristics are summarized in Table 1. 
2. Surgical specimens 
Transurethral resection or radical prostatectomy specimens were snap frozen. Sections 
of 4-6 μπι thickness were cut on a cryostat, air-dried, and stored at -20°C until use. One 
section from each patient was stained with hematoxylin and eosin to assess the 
histopathological grade according to Gleason (16). In this group of patients, tumor grade 
ranged from Gleason score 4 to 10. 
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Table 1: Patients characteristics (at diagnosis, n= 89) 
No. (%) 
Gleason score: 
4 
5-7 
8-10 
Clinical stage: 
Tl 
T2 
T3 
T4 
Metastasis: 
No metastasis 
With metastasis 
Unknown* 
Initial treatment: 
Primary TUR-P 
TUR-P after recurrent disease 
Radical Prostatectomy" 
11 
39 
39 
17 
29 
30 
13 
59 
29 
1 
29 
18 
42 
(12) 
(44) 
(44) 
(19) 
(32) 
(34) 
(15) 
(66) 
(33) 
( 1 ) 
(33) 
(20) 
(47) 
*: Bone scan was not done in one patient with T4 tumor. 
b
: Followed by hormonal treatment and/or radiotherapy (in 4 cases). 
c
: TUR-P, Transurethral resection of the prostate. 
": Including 3 patients with pre-operative adjuvant hormonal therapy. 
3. Immunohistochemistry 
Indirect immunoperoxidase staining was performed as previously described (14) using 
either anti E-cadherin(Eurodiagnostica BV, Apeldoorn, The Netherlands) or HECD-1 
(Takara, Berkeley, U.S.A.) monoclonal antibodies. E-cadherin staining is localized on the 
membrane, particularly at areas of cell-cell contact. In the specimens analyzed, the area 
of worst differentiation was used for immunohistochemical analysis, ie the sample was not 
randomly chosen. To assess the staining we used the following criteria: uniformly positive, 
uniformly negative or heterogeneous (mixed populations of positive and negative stained 
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cells) as described by Schipper et al. (17). Besides positive or negative staining, some 
tumors showed a cytoplasmic staining, which was also considered to be abnormal and 
included in the criteria for heterogeneous staining. Uniformly positive staining patterns 
were regarded as normal while uniformly negative and heterogeneous stainings were 
considered as aberrant expression. 
4. Statistical analysis 
The correlation of E-cadherin expression with tumor grade, clinical stage, pathological 
stage and metastases was evaluated by the chi-square test readjusted where necessary 
with the Yates correction. The value of significance was taken as p<0.05. Actuarial 
survival rate of patients with normal and decreased E-cadherin expression were evaluated 
according to Kaplan-Meier(18), and the differences were tested with log-rank test. The 
statistical software used was Statistical Package for the Social Sciences (Chicago, USA). 
Results 
Eighty-nine snap frozen prostate cancer specimens were stained with the anti-E-cadherin 
monoclonal antibodies anti-E-cadherin or HECD-1 and scored as described previously 
(14). The scoring system is based on the biological functional relation between loss of E-
cadherin expression and invasiveness, i.e., the presence of a negative subpopulation is 
considered to have important biological significance. In Figure la, an example of normal 
expression can be seen with uniformly positive staining on the membrane at cell-cell 
contacts. Abnormal patterns comprise partially positive and partially negative stainings 
on the membrane or a cytoplasmic staining (Fig. lb). Occasionally, no E-cadherin 
expression at all was found in the entire tumor area evaluated (Fig. lc). Both of the 
latter staining patterns were regarded as aberrant expression of this molecule. 
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Fig. ΙΑ, normal staining, in the well differentiated tumor staining is confined to the the cell 
cell contacts. B, heterogeneous staining. Positive membraneous staining on some of the cells 
whereas others are negative. C, completely negative staining, none of the tumor cells are 
stained. 
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1. Correlation between decreased E-cadherin expression and local and distant progression 
of the tumor. 
In a previous study we found that E-cadherin expression correlated significantly with 
tumor grade (Gleason score) in human prostate cancer (14). Considering the putative 
consequences of loss of E-cadherin function, Le., acquisition of an increased invasive 
potential, we evaluated whether aberrant E-cadherin expression also correlated with stage 
and the presence of metastasis. Indeed, there was a correlation between degree of local 
extension of the tumor and aberrant expression of E-cadherin (Table 2). All well 
differentiated tumors ( n = l l ) showed normal expression, while 28% and 79% of the 
moderately - and poorly differentiated tumors respectively showed aberrant E-cadherin 
expression, which confirmed our previous study (14). The correlation between aberrant 
E-cadherin expression and local extension of the tumor (clinical tumor stage) was 
statistically significant (p < 0.005). Only 33% of the Tl-2 tumors (organ confined) 
showed aberrant E-cadherin expression compared to 63% of T3-4 tumors (locally 
invasive) (Table 2). Moreover, the presence of metastases was significantly correlated 
with aberrant E-cadherin expression (Table 2, ρ < 0.001). In tumor tissue from patients 
without metastatic disease E-cadherin expression was normal in 68% and aberrant in 
32%. On the other hand, E-cadherin expression was normal in 24% and aberrant in 76% 
of the patients that presented with metastases (Table 2). 
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Table 2: Relationship of E-cadherin expression to tumor grade, clinical stage and 
metastases. 
Gleason score: 
4 
5-7 
8-10 
Clinical stage: 
Tl-2 
T3-4 
Metastases: 
-
+ 
Normal 
No. 
11 
28 
8 
31 
16 
40 
7 
E-cadherin 
(%) 
(100) 
(72) 
(21) 
(67) 
(37) 
(68) 
(24) 
expression 
Decreased 
No. 
0 
11 
31 
15 
27 
19 
22 
(%) 
( 0 ) 
(28) 
(79) 
(33) 
(63) 
(32) 
(76) 
Significance 
of dfflference> 
p<0.001 
x2= 31.8 
ρ < 0.005 
x2= 8.1 
p<0.001 
x2= 14.9 
2. Relation between E-cadherin expression and survival. 
Previous studies on the role of stage and grade as prognostic factors for prostate cancer 
are ambiguous, in large part due to the limited accuracy of clinical staging procedures. 
Once pathological staging is taken into account, stage becomes an important prognostic 
factor (7). Pathological staging is only available in case of radical surgery, hence 
additional tools are urgently needed. We, therefore investigated the relation between E-
cadherin expression and survival. The average follow up time for patients who were still 
alive at the time of evaluation was 36 months (range: 12 to 71 months). The 3 year over­
all survival rate of patients with normal E-cadherin expression was significantly higher 
than for patients with aberrant expression [(log rank test: chi-square= 20.4, p<0.001 (Fig. 
2)]. The group of patients described above is heterogenous, hence we stratified according 
to treatment, i.e. radical prostatectomy versos palliative TUR-P. 
-t 1 ! (normal expression, η = 47) 
-Η-H (t—I—I Η—ι 
Ul 
30 36 
time in months 
Fig. 2. Kaplan-Meier overall survival rate related to E-cadherin expression. Лага, censured 
data. Log rank test: chi-square= 20.4, p<0.001. 
3. Progression after radical prostatectomy. 
The characteristics of the patients treated by radical prostatectomy are summarized in 
Table 3. Eleven of 42 patients (26%) had evidence of disease progression (clinical or 
biochemical progression, i.e., PSA>0.5ng/ml) after 8 to 42 months. All of them but one 
(91%) showed aberrant E-cadherin expression in their tumor specimens (Table 3). 
Further analysis showed a significant correlation (log rank test: chi-square= 9.4, p<0.005) 
between aberrant E-cadherin staining and progression as presented in Figure 3. 
Among the patients which have capsular penetration (pT>3), 8 had aberrant E-cadherin 
expression and 7 out of them progressed while 5 had normal E-cadherin expression and 
only one of them progressed (Table 3). 
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4. Progression after palliative TUR-P. 
Forty-seven patients with advanced disease were treated by transurethral resection of the 
prostate (TUR-P). We can divide this group into primary TUR-P followed by hormonal 
treatment and/or occasionally radiotherapy and TUR-P after hormone escaped disease 
(Table 1). In the primary TUR-P group, the analysis of survival within 3 year after tumor 
resection shows that aberrant staining is significantly correlated with poor prognosis [log 
rank test: chi-square= 15.1, p<0.001 (Fig. 4a)]. The mean survival of patients with 
hormone escaped disease who underwent a TUR-P was 25 months for patients with a 
normal E-cadherin expression and 17 months for patients with a decreased expression. 
However, the 3 year survival analysis of this group shows no significant correlation 
between decreased immunoreactivity and survival [log rank test: chi-square=1.2, p<0.3 
(Fig. 4b)]. 
% of patients 
without progression 
100-
(normal expression, η - 27) 
1—« 1—I H-i HI—ь· 
(aberrant expression, η - 15) 
30 36 
time in months 
Fig. 3. Kaplan-Meier progression free rate in patients after radical prostatectomy. Ban, 
censured data. Log rank test: chi-square= 9.4, p<0.005. 
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Ч survival 
100 
• 
I 
(normal expression, η - 14) 
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(aberrant expression, η - 15) 
— ι · 
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L 
30 36 
time in months 
% survival 
100 
20 
ί 
• 
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(normal expression 
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η - 6) 
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Fig. 4. Kaplan-Meier survival curves. Ban, censured data, a, 3-year survival related to E-
cadherin expression in patients with primary TUR-P*: Log rank test: chi-square= 15.1, 
ρ < 0.001. b, 3-year survival of patients with TUR-P after recurrent disease according to 
E-cadherin expression: Log rank test: chi-square= 1.2, ρ < 0.3. 
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Discussion 
The relation between E-cadherin expression and grade is now well documented for 
several carcinomas (17,19-23) including prostate cancer (14). To evaluate the potential 
use of E-cadherin immunohistochemistry as a prognostic factor for prostatic cancer 
patients, we analyzed 89 prostate cancer specimens. We show that aberrant E-cadherin 
expression (heterogeneous, cytoplasmic or negative) was found in 33% (15 of 46) of the 
tumors that were clinically found to be organ confined (Tl-2), and in 63% (27 of 43) of 
the lesions that extended beyond the prostatic capsule (T3-4). Moreover, 76% of the 
patients that were diagnosed with metastatic disease showed aberrant E-cadherin 
expression patterns. This is in good agreement with a study by Schipper et al. (17) and 
Mattijssen et al. (24) on squamous cell carcinoma of the head and neck that revealed a 
close correlation, not only between aberrant E-cadherin expression and grade, but also 
with presence of lymph node metastases. Furthermore, we now show that overall survival 
correlated significantly with aberrant E-cadherin expression. When we stratified according 
to treatment, Le., radical prostatectomy for localized disease versus palliation in case of 
locally or distantly metastatic prostate cancer, E-cadherin immunohistochemistry had still 
prognostic value. It was most striking to see that progression after radical prostatectomy 
occurred in 67% (10 of 15) patients with aberrant E-cadherin expression, and only in 4% 
(1 of 27) of patients with normal E-cadherin staining. The correlation between aberrant 
E-cadherin expression and poor prognosis was also evident within the group of patients 
with tumors that extended beyond the prostatic capsule. Thus, this is the first study that 
suggests E-cadherin immunohistochemistry to be of value as prognostic factor in prostate 
cancer. 
It should be noted that not in all of the patients E-cadherin expression was indicative for 
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progression. This may be explained by impaired catenin function through which E-
cadherin is anchored to the cytoskeleton (8,25). A recent study by Shimoyama et a] 
suggests that loss of alpha-catenin expression can be causally related to dysfunction of 
Cadherin mediated interaction in a lung cancer cell line (PC9) (26). More recently, 
Morton et al found that in a prostate cancer cell line (PC3) impaired E-cadherin function 
could be explained by homozygous deletion of the alpha-catenin gene (27). This 
phenomenon might explain the discrepancy between normal E-cadherin expression and 
the presence of metastasis at time of diagnosis. Other mechanisms that can lead to 
dysfunction of Cadherin mediated interaction, are increased tyrosine phosphorylation of 
ß-catenin (28), or mutational inactivation of the E-cadherin function itself. The latter 
possibility is particularly interesting since the chromosomal segment to which E-cadherin 
is mapped (16q21), is frequently lost in prostate cancer development (29,30). As yet the 
mutational inactivation of E-cadherin function has not been found in human prostate 
cancer, and only reported for a subset of endometrial carcinomas (31) and gastric cancers 
(32) 
Nevertheless, irrespective of the exact mechanism, the loss of E-cadherin function 
apparently marks the loss of epithelial integrity which in turn can be an important step 
in the progression of cancer. It should be noted that although these findings seem 
convincing, the follow up is relatively short. Considering the urgent need for progression 
markers in prostate cancer, a large scale prospective study is hereby suggested, to 
establish the place of E-cadherin immunohistochemistry in prostate cancer prognoses. 
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Abstract 
E Cadherin, an intercellular adhesion molecule, has been shown to behave as an invasion 
suppressor gene in vitro. This may explain the inverse relation between expression of E 
Cadherin and tumor grade that was found in certain cancers. We therefore examined E-
cadherin expression in bladder cancer samples from patients with known clinical follow 
up. Forty nine snap-frozen specimens (24 superficial and 25 invasive tumors) and 4 
samples of normal urothelium were retrospectively analysed with anti E-cadherin 
monoclonal antibodies. In normal urothelium E Cadherin is expressed homogeneously 
with a typical membranous staining at cell-cell borders. Decreased expression is found 
in 5/24 superficial tumors and in 19/25 invasive cancers. Completely negative tumors are 
infrequent (4 cases). Most of the times a heterogeneous staining, which may correspond 
to an unstable E Cadherin expression during tumor development, is seen. Decreased E 
Cadherin expression correlates with both increased grade and stage (c2 = 9.5, ρ < 0.01 
and c2 = 14.9, ρ < 0.005 respectively). More importantly, abnormal E Cadherin expression 
correlates with shorter survival (Log rank test: c2 = 16.5, ρ < 0.001). In keeping with its 
in vitro invasion suppressor function, decreased E Cadherin expression correlates with the 
clinical aggressiveness of bladder tumors. This is the first report of E Cadherin being a 
marker with prognostic value. This parameter has now to be tested in a large prospective 
study to assess its precise clinical relevance. 
Introduction 
Bladder cancer is characterized by a diverse biological behaviour, in which acquisition of 
the metastatic capacity is clinically most relevant. Despite intra- and inter-observer 
inconsistencies, tumor grade and stage are to date the best prognostic factors. Several 
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molecular parameters (e.g. blood group antigen expression, DNA content) have been 
tested for prognostic value but none of these proved to be superior to classical 
pathological parameters. Thus there is still a paucity of markers for bladder tumor 
aggressiveness (1). Clearly, identification of the molecular steps associated with the 
acquisition of metastatic ability is important and should enable the design of diagnostic 
methods with predictive value. 
To metastasize, cancer cells have to be released in the blood or lymphatic stream. 
Decreased intercellular adhesiveness favours detachment of tumor cells and may play a 
role in the early steps of the metastatic process. Although cell-cell adhesion is a complex 
mechanism involving at least four families of adhesion molecules (integrin, 
immunoglobulin, selectin and Cadherin families), several lines of evidence indicate that 
the Ca**-dependent, E Cadherin mediated adhesiveness is critically important for 
epithelial integrity (for review see 2). Indeed, anti-Ε Cadherin antibodies (also called anti-
uvomorulin) profoundly disturb the epithelial junctional complex (3-5) and prevent mouse 
morula compaction (6). Conversely, inactivation of other systems (N CAM or b, integrin) 
has little effect on cell-cell cohesion when Cadherin adhesiveness is not impaired (7,8). 
The causal relationship between decreased E Cadherin expression and acquisition of 
invasive capacity has recently received strong support: modulation of E Cadherin function 
of several tumor cell lines either by blocking antibodies or by transfection experiments 
revealed an invasion suppressor role in vitro, for E Cadherin mediated cell-cell adhesion 
(9-11). 
As far as bladder cancers are concerned, 3 cell lines have been tested for both E-
cadherin expression and in vitro invasiveness. The RT4 and RT112 cell lines express E 
Cadherin and are not invasive, whereas the EJ24 cell line does not express E Cadherin 
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and is invasive (10). However, data on tumor specimens are almost completely missing 
(Edelman et al (12) found a normal staining pattern in 2 TCC). In a search for more 
accurate prognostic factors, we investigated E Cadherin expression in bladder tumors. We 
report here results of E Cadherin immunostaining and confront them with 
histopathological and survival data. 
Materials and methods 
Twenty four snap frozen superficial carcinomas (pTa-pTl) and 25 invasive carcinomas 
(pT > 2) have been analysed. Superficial tumors comprised 2 recurrences of previously 
analysed tumors. Among the invasive tumors, 2 were squamous cell carcinomas. All the 
other tumors were transitional cell carcinomas. Pathological and clinical data of the 
patients are summarized in table 1. As normal control 2 cystectomy specimens from 
patient with non urothelial tumors and on 2 uréteres from renal cell carcinoma patients 
were used. 
Sections were fixed with 3% paraformaldehyde and permeabilized with 0.2% triton X-
100. E Cadherin immunohistological detection was performed using the HECD-1 
monoclonal antibody (British Biotech product Ltd, Abindon, U.K.) at the concentration 
of mg/ml. Furthermore, 43 tumors were also stained with the L-CAM monoclonal 
antibody (Eurodiagnostic, Apeldoorn, The Netherlands) used at a 1/10 dilution. As 
previously described (13), a classical immunoperoxidase technique was used to reveal E 
Cadherin immunoreactivity. 
Evaluation of E-cadherin expression used a classification derived from Shiozaki et al (14): 
tumors were classified as normal if the staining was similar to that of normal urothelium. 
Abnormal tumors were negative (i.e. complete absence of immunoreactivity) or 
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heterogeneous (i.e. when the tumor is composed of positive and negative areas). We also 
noticed cytoplasmic immunoreactivity in some cases. When it was associated with 
negative areas the tumor was classified as heterogeneous. E Cadherin expression has been 
scored in blind by 3 persons. 
For statistical analysis, a c2 test was used for the correlations with pathological data. The 
log rank test has been employed for survival analysis. 
table 1: E Cadherin staining, clinical and pathological data of each patient 
Ch: chemotherapy; Ct: cystectomy; R: radiotherapy; 
TURT: transuretral resection of the tumor, 
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53 
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39 
40 
41 
42 
43 
44 
45 
46 
47 
62 
65 
83 
79 
61 
59 
73 
73 
76 
68 
63 
74 
50 
70 
75 
44 
82 
3 
3 
3 
3 
3 
3 
3 
3 
2, 
sec 
3 
3 
3 
2, 
sec 
2 
3 
3 
2 
¡ 2 
» 2 
» 2 
>2 
» 2 
» 2 
2-3 
2-3 
2-3 
2-3 
3 
3 
3 
3b 
3b 
4 
4 
Normal 
Negative 
Heterogeneous 
Heterogeneous 
Heterogeneous 
Heterogeneous 
Negative 
Heterogeneous 
Heterogeneous 
Heterogeneous 
Negative 
Heterogeneous 
Heterogeneous 
Normal 
Heterogeneous 
Normal 
Heterogeneous 
>27 
>66 
21 
10 
15 
3 
2 
9 
32 
2 
5 
10 
5 
>21 
>29 
>25 
5 
TURT, Ch, R 
TURT, Ct 
TURT, R 
TURT, Ct 
TURT. Ch, R 
TURT. R 
TURT, R 
TURT 
TURT, Cl, R 
TURT 
TURT, R 
Ct, Ch 
TURT 
Ct 
TURT, R, α 
TURT, Ct 
TURT 
Table 1 (continued) 
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Results 
In normal urothelium, only the cell-cell borders are stained as described for other 
epithelial tissues (i.e. the luminal membrane (arrow heads on fig 1) and the part of 
the cells in contact with the basement membrane (arrows on fig 2a) do not react with 
the anti-Ε Cadherin antibody). The arrows in fig 1 indicate a focal stronger reactivity 
at the apical part of the lateral membrane, probably reflecting the E Cadherin 
enrichment at the junctional complex (zonula adherens). Twenty six tumors show a 
similar staining pattern referred as normal staining (fig 2a) whereas 23 specimens 
present an abnormal E Cadherin expression (table 1). Only 4 tumors are completely 
negative (fig 2c). The prevailing abnormal pattern is heterogeneous, certain parts of 
the tumor being positive and others negative. In most of those cases, multiple foci of 
negative carcinomatous cells are found (fig 2b). In certain tumors with heterogeneous 
immunoreactivity, a capping of E Cadherin can be seen in some cells (arrows on fig 
2b). In two cases, immunoreactivity is found rather in the cytoplasm than at the 
membrane. One of these tumors (# 47) showed also negative areas and was therefore 
classified as heterogeneous 
Confrontation of the E Cadherin expression results with the classical histopathological 
data (table 2) reveals that abnormal E Cadherin expression is correlated with both 
grade and stage (c2 = 9.5, ρ < O.Oland c2 = 14.9, ρ < 0.005 respectively). The mean 
age of patients, 65.3 ± 2.6 for patients with a normal staining versus 68 ± 2.6 for 
those with an abnormal one, is not significantly different. Analysis of the survival 
during 3 years after tumor resection shows that abnormal immunoreactivity is strongly 
correlated with poor prognosis (c2 = 16.5, ρ < 0.001 - fig 5). This correlation seems to 
persist when only invasive tumors are analysed (c2 = 3.7, ρ < 0.06 - fig 6). For 
104 Chapter 5 
superficial tumors, too few events (3 deceases and 1 progressive disease) have been 
observed to enable any analysis of this subgroup. 
Grade 
1 
2 
3 
E Cadherin staining 
normal abnormal 
9 3 
11 6 
5 15 
stage 
superficial 
invasive 
E Cadherin staining 
normal abnormal 
19 5 
6 19 
table 2: E Cadherin staining according to histopathological data. The frequency of 
abnormal staining increase with both grade and stage (c2 = 9.5, ρ < 0.01 and c2 = 
14.9, ρ < 0.005 respectively). 
Decreased Ε-Cadherin immunoreactivity in patients with bladder tumors Ю5 
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i f 
Figure 1: 
Normal urothelium showing a staining at the cell-cell borders. The luminal 
membranes of the superficial cells (arrowheads) are devoid of staining. Arrows point 
reinforced stainings probably corresponding to junctional complexes. Due to folding 
two luminal surfaces are facing each other (400 X). 
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Figure 2: а: Transitional cell carcinoma with a conserved staining at the cell-cell 
border. As in normal urothelium, a lack of immunoreactivity is seen along the cell 
surface in contact with the basement membrane (arrows). 
b: Heterogeneous staining: Some cells show a clear staining at the cell-cell border 
whereas other areas are negative. Arrows are pointing the capping observed in some 
cells 
Decreased Ε-Cadherin immunoreactivity in patients with bladder tumors Ю7 
WW, ν*· a 
^ * S » 4 í t f * . '*Vf* ·• 
"" . ¿fer·; ч ·> Ч £ -
Ш
І А. P . 
с & f: negative staining: All the cells are completely negative, (c: 200 X; f: 400 X) 
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Discussion 
In this study, we have investigated E Cadherin expression in normal and transformed 
urothelium. Normal urothelial cells express E Cadherin homogeneously at all cell-cell 
borders. Reasoning that, according to the theory of the clonal evolution of tumors, the 
more aggressive clone within a cancer will determine the tumor behaviour (15), we 
based our grading system on the presence of a negative sub population. Since E 
Cadherin is thought to function as an invasion suppressor gene, tumors with only a 
minor fraction of negative cells should be able to invade, and thus have to be 
regarded as abnormal with respect to E Cadherin expression. We show that abnormal 
staining pattern (negative, cytoplasmic or heterogeneous) are found in 21% (5/24) of 
the superficial tumors, and in 76% (19/23) of the invasive tumors. Taken together with 
the experimental demonstration of a causal relationship between impaired E Cadherin 
function and invasiveness (9-11), this strong correlation with tumor stage seems to 
indicate that indeed disturbance of E Cadherin expression plays a role in bladder 
tumors invasiveness. 
It is striking to see that in most cases (19/23), tumors are not completely negative but 
are composed of positive and negative areas. Similar findings are reported by Shiozaki 
for oesophagus, stomach and breast cancers. The proportion of heterogeneous tumors 
is less in the study of Schipper et al (16) on squamous cell carcinomas of the head 
and neck, possibly due to the use of immunofluorescence which does not allow 
simultaneous assessment of both morphology and staining. Heterogeneous E Cadherin 
expression has also been found in the metastatic variant of a murine ovarian cell line. 
Since this heterogeneity persists upon sub cloning it is thought to reflect unstable E 
Cadherin expression (17). Thus, this staining pattern may indicate that unstable E 
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Cadherin expression occurs during tumor development. Using Η-ras transformed 
Madin Darby Canine Kidney cells, Mareel et al have obtained evidence that host 
factors play a role in this unstable E Cadherin expression. Indeed, these cells 
homogeneously express E Cadherin in vitro whereas tumors obtained after injection in 
nude mice are heterogeneous; this E Cadherin down-modulation is completely 
reversible within 8 in vitro passages of cells derived from heterogeneous metastasis 
(18). 
However other mechanisms may also lead to impaired E Cadherin function. It has 
been shown that the cytoplasmic tail of E Cadherin interacts with 3 molecules 
(Catenins a, b and g) which bridge E Cadherin to the cytoskeleton and that E Cadherin 
function is dependent on its proper anchorage to the cytoskeleton (19-21). 
Interestingly, Shimoyama recently reported that a catenin is lacking in 45.8 % of 
gastric carcinoma of the scatter type (22) with an apparently conserved normal E 
Cadherin staining (23). The cytoplasmic immunoreactivity found in two bladder tumors 
might be caused by disturbance of E cadherin-cytoskeleton interaction. Conversely, 
those cases can be a mere artefact due to cell retraction during freezing. However 
cytoplasmic immunoreactivity has also been noticed by Shiozaki et al in their study on 
oesophageal, stomach and breast cancer, and by Inoue et al. in gynecologic tumors 
(14,24). Another evidence for the possible involvement of the cytoskeleton is the clear 
capping of E Cadherin seen in some bladder tumors (fig 3). 
Based on the correlation between 16q deletion and abnormal staining pattern, 
inactivating mutations of the E Cadherin gene have been proposed (13,16,25). E 
Cadherin would thus behave as a classical suppressor gene. As far as we know, 16q 
deletions have not been documented in bladder tumors. 
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Up to now, the correlation found in certain cancers, between decreased E Cadherin 
immunoreactivity and classical prognostic parameters was the only indication for a 
potential use of E Cadherin as prognostic factor (13,14,16). Besides showing such a 
correlation in bladder tumors, our study reveals a strong correlation between 
abnormal E Cadherin staining and survival, showing that immunohistochemical 
determination of E Cadherin expression can be a useful prognostic factor for bladder 
tumors. Furthermore, the fact that decreased E Cadherin expression correlates with 
shorter survival within the group of patients with invasive disease seems to indicate 
that the prognostic value of E Cadherin staining does not merely reflect the 
correlation with stage. However, this retrospective study, on a limited number of 
cases, does not allow definite assessment of the clinical usefulness of this assay. 
Particularly, no conclusion can be drawn for patients with superficial tumors while 
early detection of aggressive tumors in those patients would improve disease 
management. For patients with invasive tumors, our results seem to indicate that 
conservation of normal E Cadherin staining is of relatively good prognosis even if the 
tumor is at an advanced stage as in case # 46. Given the rate of progression of 
superficial bladder tumors (about 4% in our series), the accurate evaluation of the 
clinical usefulness of E Cadherin immunostaining will require a large scale prospective 
study. 
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Figure 3: Kaplan-Meyer survival curves. Vertical bars represent censured data. 
a: Three year survival according to E Cadherin staining: с2 = 16.5, ρ < 0.001 b: Two year survival of 
patients with infiltrative tumors according to E Cadherin staining: с2 = 3.7, ρ < 0.06 
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Abstract 
It is now well described that E-cadherin expression correlates inversely with tumor grade 
in various carcinomas including in prostate cancer. Recently, we also demonstrated a 
statistically significant correlation between decreased E-cadherin expression and 
progression free period in early stage patients treated by radical prostatectomy and 
decreased survival in patients with advanced stage disease (Umbas, R. et al., Cancer Res. 
1994, in press). However, not every patient with normal E-cadherin expression shows 
better survival. One of the possible reasons for the loss of normal E-cadherin function 
in prostate cancer cell lines is mutational inactivation of the a-catenin gene (Morton, 
R.A. et al., Cancer Res., 53: 3585, 1993). To determine the correlation between E-
cadherin and a-catenin expression in prostate cancer, 20 patients treated by radical 
prostatectomy and 32 advanced stage patients were evaluated immunohistochemically for 
E-cadherin and a-catenin expression. The results were related to tumor grade and 
progression of the disease. Four patients in the radical prostatectomy group had aberrant 
E-cadherin and a-catenin expression and showed progression. The other 16 patients were 
free of progression and had normal E-cadherin and a-catenin expression. In the advanced 
stage group, 4 of 13 patients with normal E-cadherin staining showed aberrant a-catenin 
expression and 2 (50%) were progressed compared to only 22% progression in patients 
having both normal E-cadherin and a-catenin expression. The other 19 patients with 
aberrant E-cadherin and a-catenin staining have the poorest prognosis. These results 
suggest that loss of a-catenin immunoreactivity could be one of the mechanisms 
responsible for the loss of E-cadherin mediated cell-cell adhesion in human prostate 
cancer, and can provide additional prognostic information. 
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Introduction 
Prostate cancer is well known as a disease with an unpredictable biological potential. Not 
every patient with prostate cancer will progress (Johansson 1989, Adolfsson 1990), and 
on the other hand, metastases apparently still develop in a considerable group of patients 
that are treated radically for their localized disease (Bostwick 1993). Until now tumor 
grade and clinical stage were used as prognostic factors although pathological stage seems 
to have the best prognostic value (George 1988, Grayhack 1983, Morton 1991). 
Therefore, many studies have been done to find new prognostic markers, and one of 
these is E-cadherin, an epithelial cell adhesion molecule (Takeichi 1988). 
Loss of E-cadherin expression has been shown to correlate with the in vitro invasive 
phenotype of cancer cell lines (Frixen 1991, Bussemakers 1992). Furthermore, in human 
cancers, including prostate cancer, aberrant E-cadherin expression correlated significantly 
with increasing tumor grade (Umbas 1992). Recently we found significant correlations 
between aberrant E-cadherin expression and survival in patients with prostate cancer 
(Umbas 1994). The prognostic value seemed to be independent of tumor stage since E-
cadherin immunohistochemistry still had its prognostic value when we stratified according 
to clinical stage, i.e. patients with localized disease and those with tumors that extended 
beyond the prostatic capsule (Umbas 1994). However, not every patient with normal E-
cadherin expression shows better survival. This observation suggests that there might be 
mechanisms in these cancer cells which suppress E-cadherin function even in the 
presence of the protein as demonstrated immunohistochemically (Shimoyama 1991, Oka 
1992). Morton et al. (1993) demonstrated that loss of normal E-cadherin function in 
prostate cancer cell lines can occur through mutational inactivation of the α-catenin gene. 
Recently, Kadowaki et al. (1994) have shown that α-catenin immunohistochemistry has 
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additional prognostic value for oesophageal carcinoma. These findings prompted us to 
investigate the relationship between E-cadherin and a-catenin expression in prostate 
cancer patients. 
Materials and methods 
1. Patients. 
Twenty early stage prostate cancer patients and 32 advanced stage patients were included 
in this study. Treatment options were radical prostatectomy for early stage and hormonal 
treatment for advanced disease. Follow up was done by measuring prostate specific 
antigen level and bone scan was performed to detect metastatic lesions. 
2. Surgical specimens. 
All of these tissues were obtained at the time of surgery, either radical prostatectomy or 
transurethral resection, and snap frozen. Four to six mm serial sections from the frozen 
tissues were cut on cryostat and air dried, then were stored at -20 С until use. One 
section from each patient was stained with hematoxylin and eosin to determine the 
histopathological grading using the Gleason score system (Gleason 1977). 
3. Antibodies. 
L-CAM (uvomorulin) monoclonal antibody against E-cadherin (Eurodiagnostica BV, 
Apeldoorn, The Netherlands), and a-18, a rat monoclonal antibody against a-catenin 
(Shimoyama 1992), a kind gift from Dr Hirohashi, were used in this study. 
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4. Immunohistochemistry. 
Immunohistochemistry was performed by using indirect method as described previously 
(Umbas 1992) except that we used biolinylated (Amersham) anti-mouse Ig (E-cadherin) 
and anti-rat Ig (α-catenin) staining as secondary antibody and incubated with avidin-
biotin-peroxidase complex (Vectastain ABC kit; Vector Laboratories Inc., Burlingame, 
CA) before incubation with diaminobenzidine 0.6 mg/ml in 0.65% imidazol/Phosphate-
buffered saline. 
E-cadherin and α-catenin staining patterns were scored as described before (Schipper 
1991, Umbas 1992): uniformly positive staining was regarded as normal, while 
heterogeneous, uniformly negative and cytoplasmic stainings were scored as aberrant. 
Results 
As earlier reported there was significant correlation between E-cadherin expression and 
tumor grade (Umbas 1992). More recently, in the clinical follow up, we found that E-
cadherin staining was significantly correlated with tumor stage and survival in the 
advanced stage patients and progression free interval in patients with low stage disease 
treated by radical prostatectomy (Umbas 1994). 
In this present study we found a significant correlation between α-catenin and E-cadherin 
expression (Table 1; x*= 38.2 ,p<0.000). Nevertheless, three staining combinations could 
be discriminated: first, normal expression of both E-cadherin and α-catenin (Fig.lA, B); 
second, normal E-cadherin expression and aberrant α-catenin staining (Fig 1С, D); and 
third, both aberrant expression of E-cadherin and α-catenin. Taking together, patients 
which show normal immunoreactivity for both of these molecules have significantly better 
prognosis than patients having aberrant α-catenin expression even if the E-cadherin 
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expression was normal (Table 2;x*= 28.2, p<0.0001). 
In the radically treated group, 4 patients show aberrant E-cadherin and a-catenin 
expression and all of these patients progressed within 8 to 37 months. The other 16 
patients of this group show normal expression of both E-cadherin and a-catenin, and no 
progression could be detected in a mean follow up of 40 months (range: 20-65 months). 
Thirteen patients with advanced disease have normal E-cadherin expression; Nine of 
these patients have also normal a-catenin expression and 2 (22%) of them died of the 
disease while 2 (50%) of the 4 patients in this group which have aberrant a-catenin 
expression died (Table 3). The other 19 patients which have both aberrant expression of 
E-cadherin and a-catenin, only 3 (16%) were alive without progression and the other 16 
(84%) either showed progression (1 patient) or died of the disease. 
Table 1: Correlation between E-cadherin and a-catenin expression. 
a-catenin 
Normal Aberrant 
E-cadherin 
Normal 25 4 
Aberrant 0 23 
x*= 38.2, p<0.0001 
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Table 2 : Correlation between E-cadherin and α-catenin expression and progression 
Progression 
+ 
Normal E-cadherin 
and α-catenin 23 2 
Normal/aberrant E-cadherin 
aberrant α-catenin 5 22 
x*= 28.2, p<0.0001 
(n= 52) 
Fig.l: Immunohistochemical analyses of two representative prostate cancer specimens with anti-E-cadherin 
(A, C) and anti-alpha-catenin (alpha 18; B, D). Note the concordance in staining in A and В (upper 
panel), whereas, alpha catenin is heterogeneous (D) despite normal E-cadherin immunoreactivity (C) in 
the other sample (lower panel). 
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Table 3: Correlation between E-cadherin and a-catenin in advanced cases (n= 32). 
Patients outcome 
Progression (-) Progression (+) 
Normal E-cadherin 
and o-catenin 7 (78%) 2 (22 %) 
Normal E-cadherin 
and aberrant a-catenin 2 (50%) 2 (50 %) 
Aberrant E-cadherin 
and a-catenin 3 (16%) 16 (84 %) 
Discussion 
The use of E-cadherin immunohistochemistry has now gained considerable interest in the 
diagnosis and prognosis of carcinomas (Beherens and Birchmeier, 1993). Recently we 
reported that decreased expression of this epithelial cell-cell adhesion molecule is 
indicative for a worse clinical course of the disease (Umbas, 1994). In an attempt to 
establish the mechanisms associated with impaired Cadherin function Morton and 
coworkers found that alpha-catenin, a protein essentia] for linkage to the cytoskeleton, 
was absent due to homologous deletion of the gene (Morton, 1993). Evidence that this 
could have implication for the diagnostic use was first reported by Kadowi et.al (1994), 
i.e. a group of tumors with a normal E-cadherin pattern showed absence of alpha-catenin. 
In our study we too find that there are tumors homogeneously postive for E-cadherin, 
despite the absence for immunoreactivity against alpha-catenin, albeit that this cohort is 
much smaller than that reported for esophagal carcinomas (Kadowi, 1994). In the cohort 
of patients that was studied, only four out of 39 tumors that appeared to be normal for 
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E-cadherin, showed aberrant expression of alpha-catenin. Interestingly two of those had 
a worse prognosis, i.e. clinical progression after radical prostatectomy. Importantly, all of 
the cases showing abnormal E-cadherin patterns, were also scored likewise for alpha-
catenin. Even though the numbers are small this suggests that alpha-catenin 
irnmunohistochemistry could have additional prognostic value, and may even substitute 
E-cadherin in this respect. It should be noted, however, that due to the experimental 
uncertainties in immunohistochemical analyses the combined use of both antibodies is 
recommendable. Thus, we conclude that indeed in human prostate cancer alpha-catenin 
deficiency may be related with defective Cadherin function, and the herewith associated 
poorer prognosis, however, the high concordance between alpha-catenin and E-cadherin 
irnmunohistochemistry suggests that this is only the case in a minority of cases. The 
mechanisms underlying this lack of alpha-catenin staining despite the normal E-cadherin 
expression are not resolved yet. It has been shown that the loss of alpha-catenin can be 
causally related to the impaired Cadherin function, i.e. reintroduction of the neural alpha-
catenin in the PC9 carcinoma line lacking alpha- catenin, restored the calcium dependent 
adhesiveness, and resulted in a reversion of the morphology (Hirano, 1992). Hence, it is 
tempting to speculate that in fact alpha-catenin can function as an invasion suppressor 
gene in a subset of prostate cancer. Clearly, experimental evidence for this has to be 
obtained by detailed molecular genetic analysis of the alpha-catenin gene in these cases. 
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SUMMARY 
As described in Chapter I prostate and bladder cancer are the most frequently occurring 
malignancies in the urological field. Even more, prostate cancer is the most prevalent 
form of cancer in Western males, and the second cause of cancer related death. Both 
diseases are characterized by their unpredictable natural course and treatment outcome. 
In this respect, prognostic factors that can predict the tumor biological aggressiveness of 
a cancer are urgently needed especially since the individual therapeutic decisions are 
likely to contribute to an improvement in the treatment outcome. Besides tumor stage 
and grade as traditionally used prognostic markers, molecular markers have now gained 
considerable interest. In this chapter an overview is presented of the markers available 
to date and their potential in cancer diagnosis. 
In order to gain insight in the cell biological processes that occur during prostate cancer 
development, the intermediate filaments proteins from the keratin family were used as 
markers for cellular differentiation of epithelia. 
Chapter II describes the staining patterns of a comprehensive panel of monoclonal 
antibodies against keratins 4, 5, 7, 8, 10, 13, 14, 16, 17, 18, 19, and keratin "basal" 
individually in non-malignant as well as malignant prostate tissues. It appeared that at 
least 8 keratins were expressed in non-malignant prostatic acini, either in both basal and 
luminal cells (keratins 7, 8, 19, 5&8, and "basal") or spatially restricted to predominantly 
basal (keratin 14 and 17) or luminal cells (keratin 18). In this immunophenotype as 
compared to that in malignant prostate tissue, the loss of the basal cell restricted keratin 
14 and 17 was most evident. Thus, these two keratins could be a valuable tools to 
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discriminate between non-malignant and malignant prostatic tissue. In the malignant 
processes expression of keratins 8, 18 and 19 was retained. Also the antibody RCK103 
showed immunoreactivity, quite similar to LP2K (anti-keratin 19). Both antibodies, 
RCK103 and LP2K are reactive to basal cells in the non-malignant acini, hence prostate 
cancer has a keratin phenotype with primarily luminal cell characteristics, but with 
definite basal cell traits, which became less abundant in the high grade lesions. On the 
basis of the stem cell model for prostate epithelial differentiation we suggest that the 
putative amplifying cells are the target for neoplastic transformation. 
Clearly, the primary interest of this thesis was to investigate rather molecular prognostic 
markers instead of differentiation markers. One of the candidate markers is E-cadherin, 
a Ca2*-dependent cell-cell adhesion molecule. Interestingly, the chromosomal regions 
16q21.3 to which the E-cadherin gene has been mapped was frequently involved in allelic 
loss in both primary and metastatic deposits of prostate cancer. In a previous study of the 
Dunning R-3327 rat prostatic cancer model system, the expression of E-cadherin was 
retained in non invasive tumor lines while all established lines with high invasive potential 
showed no detectable levels of E-cadherin expression. 
In chapter III we studied the expression of E-cadherin in non-malignant and malignant 
prostate tissues and we found that E-cadherin staining was reduced or absent in more 
than half of the tumors when compared to non-malignant prostate, which consistently 
showed normal (i.e., positive) staining. There was a statistically significant correlation 
between the aberrant (i.e., heterogeneous and negative) expression of E-cadherin and loss 
of tumor differentiation. In respect to the clinical value of these findings it is of particular 
interest to note that within the group of patients with moderately differentiated tumors, 
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comprising the majority of cases observed clinically, a discrimination could be made 
between normally staining and aberrantly staining tumors. Moreover, the percentage of 
tumors with aberrant E-cadherin staining increased when clinically localized tumors were 
compared to either tumors with extensive local progression or metastatic deposits of 
prostate cancer, suggesting a correlation between loss of E-cadherin and tumor 
progression. These findings prompted further investigations on the usefulness of E-
cadherin as a prognostic marker. 
Chapter Г describes the prognostic value of E-cadherin expression in addition to tumor 
grade and stage in patients with prostate cancer. As previously reported, a significant 
inverse correlation was found between E-cadherin expression and tumor grade. 
Importantly, we showed that aberrant E-cadherin expression was found in 33% of the 
lesions that were clinically found to be organ confined, and in 63% of the lesions that 
extended beyond the prostatic capsule. Aberrant staining was also significantly higher in 
the primary tumors from patients that presented with metastases when compared to 
those without metastases. Furthermore, the overall survival correlated significantly with 
aberrant E-cadherin expression. When we stratified according to treatment (radical 
prostatectomy for patients with localized disease versus hormonal treatment in case of 
disseminated disease), E-cadherin immunohistochemistry had still its prognostic value. In 
the group of localized disease treated by radical prostatectomy, aberrant E-cadherin 
expression was significantly correlated with tumor progression either clinically or 
biochemically. While in the group of disseminated disease, aberrant E-cadherin staining 
was significantly correlated with shorter survival. Thus, this is the first study that suggests 
E-cadherin immunohistochemistry to be of value as prognostic factor in prostate cancer. 
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However, not in all of the patients E-cadherin expression was indicative for progression, 
so, a large scale prospective study is suggested to investigate the usefulness of E-cadherin 
expression in this respect. 
Bladder cancer is the second most prevalent urological cancer which is characterized by 
variable nature and aggressive potential. It is obvious that inclusion of prognostic factors 
can be important in an individual therapeutic approach aimed improving the efficacy, for 
instance, by changing to a more aggressive therapeutical modalities before tumor 
progression can occur. In this respect, E-cadherin expression has been demonstrated to 
have a correlation with tumor invasiveness in bladder cancer cell lines. 
In chapter V we studied the E-cadherin immunostaining in bladder specimens from 
patients with non-malignant urothelium as well as in bladder tumors and compared them 
with histopathological and survival data. In normal urothelium, E-cadherin expression is 
homogeneous with a typical membraneous staining at cell-cell bordes. Furthermore, we 
found that aberrant expression is more often found in patients with invasive cancer 
compared to patients with superficial tumors. Aberrant E-cadherin expression also 
significantly correlated with increasing grade. More interestingly, aberrant E-cadherin 
expression significantly correlated with shorter survival. Thus, these findings indicate E-
cadherin to be a potential marker with prognostic value. 
However, not every patient with normal E-cadherin immunoreactivity shows better 
survival. These observations suggest that there might be a mechanism in the cancer cell 
through which E-cadherin function is suppressed even when at immunohistochemistry the 
protein is still detectable. Recent study reported that loss of normal E-cadherin function 
in prostatecancer cell lines can occur through mutational inactivation of the a-catenin 
gene. 
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Chapter VI reports on the additional prognostic value of a-catenin in prostate cancer 
patients. We found a significant correlation between a-catenin and E-cadherin expression 
in prostate cancer. In the radically treated group, a-catenin staining shows the same 
results as E-cadherin expression with respect to the progression-free survival interval. 
Interestingly, in the advanced cases a-catenin expression seems to have additional 
prognostic value to E-cadherin, immunohistochemistry. In this group, patients with 
aberrant a-catenin staining have significantly poorer prognosis even if the E-cadherin 
expression was normal. 
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SAMENVATTING 
In de urologische oncologie zijn het blaas- en prostaatcarcinoom de meest voorkomende 
ziektebeelden. Het biologische gedrag van beiden is onvoorspelbaar, waardoor de uroloog 
in toenemende mate geconfronteerd wordt met dilemma's in de therapiekeuze. Hierbij 
zouden prognostische factoren een belangrijk hulpmiddel kunnen zijn, omdat met name 
individualisering van de therapiekeuze bij kan dragen aan een verbetering van het effect 
ervan. Voorshands is het nauwkeurig bepalen van de mate waarin het ziekteproces zich 
heeft verspreid, de pathologische stadiëring, een van de belangrijkste factoren, echter het 
gebruik van moleculaire karakteristieken als hulpmiddel geniet in toenemende mate 
belangstelling. In hoofdstuk een wordt een overzicht gegeven met betrekking tot de stand 
van zaken in het gebruik en potentieel van prognostische factoren. 
De cellulaire oorsprong in met name het ontstaan van prostaatkanker is nog niet 
opgehelderd. Om meer inzicht te verkrijgen in de tumorcelbiologische aspecten van deze 
ziekte kunnen celtype specifieke eiwitten, zoals die uit de groep van de intermediaire 
filamenten, een belangrijk hulpmiddel zijn. In hoofdstuk twee wordt het expressie patroon 
van de epitheelspecifieke kératines beschreven, waarbij gebruik gemaakt werd van een 
uitgebreid panel van antilichamen. Tenminste acht kératines komen tot expressie in de 
secretoire acini van de prostaat, waarbij een aantal van de kératines specifiek de luminale 
(kératine 18) of basale cellen (kératine 14 en 17) herkennen, terwijl andere in beide 
cellagen aangetoond kunnen worden (kératine 7,8,19,5 en 8). Een vergelijkende analyse 
van het kératine immunophenotype in maligne en niet maligne processen in de prostaat 
toonde aan dat kératine 14 en 17 niet tot expressie komen in prostaat carcinomas, 
waardoor een belangrijk hulpmiddel beschikbaar is gekomen om deze beide processen 
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eenduidig te onderscheiden. In de prostaatcarcinomen komen het 'luminaal specifieke' 
kératine 18, alsmede kératine 8 en 19, die in de niet maligne structuren in beide cellagen 
gevonden worden, tot expressie. Opvallend hierbij is de coexpressie van deze kératines, 
hetgeen op basis van eerder onderzoek op een fenotype duidt dat past bij de 
zogenaamde 'amplifying' cel, die gedefinieerd is als een secundaire stamcel in de prostaat 
('stamceltheorie voor de prostaat, geponeerd door Isaacs en Coffey). Deze bevindingen 
impliceren dat deze celpopulatie waarschijnlijk in de maligne ontaarding een cruciale rol 
speelt. 
Het doel van het onderzoek was om moleculaire parameters met voorspellende waarde 
voor het beloop van de ziekte te analyseren, de zogenaamde moleculair prognostische 
factoren. E-cadherine werd gekozen, onder meer omdat vooronderzoek had aangetoond 
dat de chromosomale regio waarop dit gen gelegen is, veelvuldig verloren gaat in de 
progressie van het prostaatcarcinoom. Tevens werd in studies aan een modelsysteem voor 
deze ziekte aangetoond dat verlies van E-cadherine correleerde met het invasieve gedrag 
van de tumorlijnen. Daarenboven bleek dit calciumafhankelijke adhesiemolekuul te 
kunnen functioneren als invasiesuppressor. 
Hoofdstuk 3 beschrijft de immunohistochemische analyse van prostaatcarcinomas met 
antilichamen tegen E-cadherine. Het verlies van expressie van dit eiwit bleek significant 
te correleren met de graad van de tumor. Het was met name opvallend dat binnen de 
groep van matig gedifferentieerde tumoren (Gleason score 6-8), op basis van E-cadherine 
immunohistochemie twee groepen onderscheiden konden worden. Tevens werd een 
duidelijke correlatie met de stadiering van de tumor aangetoond. Om de waarde in het 
voorspellen van het klinisch beloop te bestuderen werden deze immunohistochemische 
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bevindingen geconfronteerd met de klinische data (hoofdstuk 4), waarbij een relatief 
korte gemiddelde vervolgperiode beschikbaar was, omdat de analyses voorshands 
uitsluitend op vers ingevroren materiaal uitgevoerd konden worden. Een afwijkende E-
cadherine kleuring correleerde significant met de prognose. Bij een meer gedetailleerde 
analyse bleek dat indien werd gestratificeerd naar tumorstadium en -behandeling de 
potentiële waarde als prognostische marker behouden bleef. In de groep van patiënten 
die een radicale prostatectomie ondergingen, voorspelde E-cadherine immuno-
histochemie zeer betrouwbaar de kans op progressie van de ziekte, ook binnen de groep 
van patiënten met een lokaal of op afstand uitgezaaid proces hadden de patiënten met 
een normaal E-cadherine expressiepatroon een significant betere prognose. 
Deze studie is de basis voor een prospectieve multicentrum studie. 
Blaaskanker is de op een na meest voorkomende maligniteit die door de uroloog 
behandeld wordt. Ook deze tumor heeft vaak een zeer onvoorspelbaar klinisch beloop, 
waardoor soms te laat tot een agressieve behandeling van de ziekte wordt besloten. 
Indien de agressiviteit van een individuele tumor meer betrouwbaar voorspeld zou 
kunnen worden, kan zonder gevaar voor overbehandeling, in een eerder stadium besloten 
worden om tot radicale chirurgie over te gaan om aldus de overlevingskans van de 
patiënt te vergroten. 
In hoofdstuk 5 worden de resultaten van een immunohistochemische analyse met E-
cadherine antilichamen gepresenteerd. In niet maligne urotheel komt het celadhesie-
molekuul homogeen tot expressie aan de cel-cel contacten. Afwijkende expressiepatronen 
zoals eerder beschreven werden significant vaker gevonden in hooggradige tumoren 
welke een invasief tumorbiologisch gedrag vertoonden. Daarenboven, bleek er een 
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significante correlatie te bestaan tussen afwijkende E-cadherine expressie en een slechte 
prognose. Derhalve, kan E-cadherine immunohistochemie een uitbreiding vormen van 
het diagnostische armentarium in de moleculaire prognostiek van deze ziekte. 
Opgemerkt zij echter dat alhoewel er een overtuigende relatie lijkt te bestaan tussen E-
cadherine immunohistochemie en invasief en maligne gedrag, er toch ook uitzondering 
zijn, i.e. tumoren met een normaal expressiepatroon, die een invasief gedrag vertonen. 
Meer recente studies suggereerden dat dit mogelijk veroorzaakt werd door het verlies van 
alfa-catenine, een eiwit dat essentieel is voor de verankering van E-cadherine aan het 
cytoskelet. 
In hoofdstuk 6 wordt dan ook de hypothese getoetst of verlies van alpha-catenine 
expressie additionele waarde heeft voor de moleculaire diagnostiek van prostaatcar-
cinomen. Er werd zoals verwacht een zeer duidelijke correlatie gevonden tussen E-
cadherine en alfa-catenine immunohistochemie, waarbij voor de groep van radicaal 
behandelde patiënten de analyses identieke uitkomsten gaven. Echter in de groep van 
patiënten die gediagnostiseerd werden in een meer geavanceerd stadium, bleek in enkele 
gevallen alfa-catenine immunohistochemie een afwijkend patroon op te leveren, terwijl 
de E-cadherine expressie normaal was. Juist in deze gevallen was de prognose slechter, 
en we concludeerden dan ook dat alfa-catenine immunohistochemie mogelijk een 
sterkere prognostische waarde kan hebben. 
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